Pittsburgh University School of Law

Scholarship@PITT LAW
Articles

Faculty Publications

2019

Regulation of Encapsulated Placenta
Greer Donley
University of Pittsburgh School of Law, donley@pitt.edu

Follow this and additional works at: https://scholarship.law.pitt.edu/fac_articles
Part of the Administrative Law Commons, Feminist, Gender, and Sexuality Studies Commons, Food
and Drug Law Commons, Health Law and Policy Commons, Health Policy Commons, Law and Gender
Commons, and the Science and Technology Policy Commons

Recommended Citation
Greer Donley, Regulation of Encapsulated Placenta, 86 Tennessee Law Review 225 (2019).
Available at: https://scholarship.law.pitt.edu/fac_articles/89

This Article is brought to you for free and open access by the Faculty Publications at Scholarship@PITT LAW. It has
been accepted for inclusion in Articles by an authorized administrator of Scholarship@PITT LAW. For more
information, please contact leers@pitt.edu, shephard@pitt.edu.

REGULATION OF ENCAPSULATED PLACENTA
GREER DONLEY*
INTRODUCTION............................................227
PLACENTOPHAGY PREVALENCE, MOTIVATIONS, AND RISKS.. 229
I.
ENCAPSULATED PLACENTA: DRUG, SUPPLEMENT, OR HUMAN
II.
...... 240
.......................................
TISSUE? ..

A. The Definitions and Regulatory Requirements for Drugs,
................. 241
Supplements, and Human Tissues
and
Safety
for
Review
1. Drugs: Premarket
...... 241
........................
Effectiveness
2. Supplements: Enter the Market Directly .................. 244
..... 249
3. Human Tissues: A Bifurcated Approach ....
Mixed
Categorizing
for
Method
FDA's
B. Intended Use:
253
Products..............................
III.

PUBLIC POLICY CONCERNS IN REGULATING
PLACENTOPHAGY................................

257

A. Balancing Consumer Safety Against Consumer
Access ........................................

258

B. ConcernsAbout the PaternalisticOver-Protectionof

Women
IV.

..............................

........ 265

TOWARD A BALANCED REGULATION OF ENCAPSULATED
.........................................
PLACENTA

274

A. Intended Use Would Lead to the Wrong Result ............. 274
B. FDA Should Use Its Discretionto Regulate Encapsulated
Placentaas Both a Supplement and 361 HCT/P........... 276
1. The 361 HCT/P and Supplement Regulations Would
................. 277
Adequately Protect Consumers
2. FDA Can (and Should) Use Its Enforcement Discretion
282
.....
..................
to Achieve This Result
CONCLUSION

....................................

...... 286

The practice of placenta encapsulation is rapidly growing. It
typically involves post-partum mothers consuming their placentas as

pills in the months after childbirth. The perceived benefits include
improved mood and energy, reduced bleeding and pain, and greater
milk supply. But these effects are unproven, and consumption comes

* Greer Donley is an Assistant Professor at the University of Pittsburgh
School of Law. I would like to thank Mary Crossley, Rachel Sachs, Andrew Budzinski,
and Anya Price for their valuable and thoughtful comments on earlier drafts of the
Article.

226

TENNESSEE LAWREVIEW

[Vol. 86.225

with health risks. The rise of this trend has sparked a vigorous debate
in the recent medical literature, but this Article is the first to consider
the legal implicationsofplacentaencapsulation.This Article examines
whether FDA should regulate encapsulated placenta, and if so,
whether it should be regulatedas a drug, supplement, or human tissue.
Because the product does not fit neatly into any of FDA's
predetermined categories, the Article explores the optimal regulatory
categorizationfrom a policy and gender perspective. It concludes that
FDA should regulate encapsulatedplacenta as both a supplement and
particulartype of low-risk human tissue. The regulations associated
with these categories will sufficiently protect women without creating
such high entry barriers that the product would effectively (and
paternalistically)disappearfrom the market.
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INTRODUCTION

A trend has emerged among new mothers: post-partum placenta
consumption. This practice typically involves a provider collecting a
woman's placenta from the hospital or home after the child is born,
then dehydrating, grinding, and encapsulating the organ so that the
post-partum mother can ingest it as pills in the months following her
child's birth. The practice is called placentophagy, and though it may
seem like a fringe movement, it is becoming increasingly common,
especially after numerous celebrities publicly discussed their
experiences with it. Small placentophagy shops, which are generally
owned and operated by women, have opened all over the United
States. The majority of hospitals now have policies to facilitate the
process, and some states have enacted statutes to protect a woman's
right to her placenta.' This new trend has caused a vigorous debate in
the medical literature, 2 but this Article is the first to explore the legal
implications of placenta encapsulation.
Despite the recent popularity, the United States Food and Drug
Administration ("FDA") does not currently regulate encapsulated
placenta. Proponents of placentophagy believe that it fights postpartum depression, replaces vitamins that were depleted in the
childbirth process, and reduces post-partum bleeding and pain.
Opponents, however, respond that there is little to no research
supporting the purported health benefits of encapsulated placenta
and that the product may contain toxins or carry risks associated with

&

&

Sixty-one percent of hospitals have a policy that allows for the release of
1.
placentas. Rebecca N. Baergen, Harshwardhan M. Thaker & Debra S. Heller,
PlacentalRelease or Disposal?Experiences of PerinatalPathologists, 16 PEDIATRIC
DEVELOPMENTAL PATHOLOGY 327, 327-28 (2015).
2. See e.g., Baergen et al., supra note 1, at 327; Cynthia W. Coyle et al.,
Placentophagy: Therapeutic Miracle or Myth?, 18 ARCHIVES WOMEN'S MENTAL
HEALTH 673 (2015); Alex Farr et aL, Human Placentophagy:A Review, 218 AM. J.
OBSTETRICS & GYNECOLOGY 401 (2017); Laura K. Gryder et al., Effects of Human
MaternalPlacentophagyon MaternalPostpartumIron Status:A Randomized, DoubleBlind, Placebo-Controlled Pilot Study, 62 J. MIDWIFERY & WOMEN'S HEALTH 68
(2017); Emily H. Hayes, Consumption of the Placentain the PostpartumPeriod, 45 J.
OBSTETRIC, GYNECOLOGIC & NEONATAL NURSING 78 (2016); Rachel Joseph et al., A
Literature Review on the Practice of Placentophagia, 20 NURSING FOR WOMEN'S
HEALTH 476 (2016); Marisa Marraccini & Kathleen S. Gorman, Exploring
Placentophagy in Humans: Problems and Recommendations, 60 J. MIDWIFERY
WOMEN'S HEALTH 371 (2015); Stephanie A. Schuette et al., Perspectives from Patients
and Healthcare Providers on the Practice of Maternal Placentophagy, 23 J.
ALTERNATIVE & COMPLEMENTARY MED. 60 (2017); Sharon M. Young et al.,
Placentophagy's Effects on Mood, Bonding, and Fatigue: A Pilot Trial, Part 2, 31
WOMEN & BIRTH e258 (2017) [hereinafter Young, Pilot 2].
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consumption. These possible harms, opponents argue, underscore the
need for regulation, especially now that the practice is growing and
the risks are becoming clearer. But placentophagy advocates are
skeptical of regulation, fearing that small placentophagy providersalmost all of whom are women-cannot afford to comply with onerous
regulatory burdens; as a result, if FDA regulated the product too
harshly, providers would likely go out of business, and their product
would disappear with them.
FDA regulation always involves trade-offs-it can both protect
individuals from harm, while also impairing the public's access to
beneficial products. Balancing these concerns is particularly
complicated around pregnancy and childbirth as it necessarily
invokes criticisms on the state's overregulation of women's bodies. But
the dilemma with encapsulated placenta goes beyond gender: it also
involves questions surrounding the agency's statutory framework.
FDA's regulatory scheme centers around categories; for example,
drugs are regulated differently (and more stringently) than foods or
supplements. So even if FDA were to conclude that regulation of
encapsulated placenta is warranted, under which category should
FDA regulate it? Encapsulated placenta could arguably meet the
definition of a drug, human tissue, or supplement-categories with
vastly different regulations.
This Article explores if and how FDA should regulate
encapsulated placenta. In Part I, I provide background on
placentophagy, discussing the motivations underlying women's
decisions to purchase encapsulated placenta, the purported benefits
and risks of consumption, and the published research studying its
effects. In Part II, I review FDA's category-based regulatory scheme
for drugs, supplements, and human tissues. I explain the definition
and regulations associated with each categorization. Because
encapsulated placenta could meet the definition of three product
categories, I refer to it as a mixed product-a term I use to describe
products that fall within the definitions of numerous FDA categories.
This Part concludes with a description of how FDA typically sorts
mixed products, finding that the agency has never addressed how to
categorize a product like encapsulated placenta.
In light of this ambiguity, I argue in Part III that two policy
concerns should be considered when deciding whether and how to
regulate encapsulated placenta. First, I explore the constant tension
in all FDA regulation: the need to balance consumer access to healthrelated goods against consumer protection from unsafe or ineffective
products. Second, I highlight the centrality of gender to the debate,
looking to other examples of regulation in the pregnancy and
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childbirth context, which often overprotect women to their detriment.
I note that most consumers of encapsulated placenta see themselves
as rejecting a patriarchal medicalization of childbirth that has not
benefited them, and that overregulating the product would perpetuate
their perception that female autonomy over reproductive decision
making is not being respected. I conclude that although a regulatory
floor is necessary to ensure safe consumption of the product,
encapsulated placenta should not be regulated so harshly that women
lose access to a safe product that they perceive as beneficial. Women
deserve protection without paternalism.
Finally, in Part IV, I explain why FDA's traditional approach to
categorizing mixed products would lead to a bad policy result with
encapsulated placenta: it would either remove access to the product
entirely or fail to provide adequate protection. Instead, I argue that
FDA should use its discretion (as it has done with similar products) to
narrowly tailor the regulation of encapsulated placenta to cover only
the product's genuine risks. The main types of harms that
encapsulated placenta risks are (1) the spread of communicable
diseases resulting from improperly handled tissue and (2) the public's
deception when manufacturers claim without proof that their product
will cure, mitigate, or prevent disease. These harms can be prevented
by regulating encapsulated placenta as both a supplement and
particular kind of human tissue, designated as a 361 HCT/Pproducts with regulations designed to prevent those exact risks. These
regulations, however, would not require premarket review or proof of
efficacy: two barriers that would keep encapsulated placenta off the
market if it were regulated as a drug. Regulating encapsulated
placenta in this narrowly tailored way would provide the regulatory
floor necessary to protect women without resorting to overprotection.
I. PLACENTOPHAGY PREVALENCE, MOTIVATIONS, AND RISKS
The placenta is a vascularized organ that connects the mother to
the fetus through the umbilical cord.3 It delivers oxygen, nutrients,
and hormones to the fetus and acts as a barrier to protect the fetus
from toxins. 4 Almost immediately after a baby is born, the placenta is
5
delivered. It typically becomes medical waste, though many new uses
have emerged, including most significantly, as an ingredient for stem

3.
4.
5.

Schuette et al., supra note 2, at 60.
Id.
Baergen et al., supra note 1, at 327.
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cell research. 6 With the promise of new stem cell treatments, women
can even bank their placentas for their own future use (or the use of
a family member) under the theory that genetically matching stem
cells may be effective at treating their own diseases in the future.7
This Article examines a particular new use for the placenta: postpartum
maternal
consumption
through
placentophagy.
Placentophagy started to grow in popularity over the past two decades
and is now fairly commonplace, particularly among white, middle
class women. 8 Although there are no national estimates, in Portland,
Oregon alone, approximately 2,000 women per year consume their
placentas. 9 A long list of celebrities, including Kim Kardashian and
January Jones, have blogged and written about their experiences with
placentophagy.o Respected periodicals are discussing and debating
the practice." The Washington Post, for instance, reported on the

6. Anne 0. Glausser, The Placenta's Second Life 2 (June 9, 2009) (unpublished
master's thesis,
Massachusetts
Institute
of Technology)
(available at
https://dspace.mit.edulbitstream/handle/1721.1/54572/567779304MIT.pdf?sequence=2) ("[E]expelled placenta is used in eye surgery, in training dogs to
sniff dead bodies, in toxicology research, in forensics, in cosmetics, and, most
significantly, in an emerging field of stem cell research.").
7.
Why
Bank?, AMERICORD,
https://www.americordblood.com/banking/
placenta-tissue/ (last visited Mar. 25, 2019).
8. See, e.g., Joseph et al., supra note 2 at 480 ("[This practice is particularly
acceptable among educated, married (90%), middle-class White American women
(93%; N = 189)."); Jodi Selander et al., Human Maternal Placentophagy:A Survey of
Self-Reported Motivations and Experiences Associated with PlacentaConsumption, 52
ECOLOGY FOOD & NUTRITION 93, 107-08 (2013); Schuette et al., supra note 2, at 6263.
9. Sharon M. Young et al., Presence and Concentration of 17 Hormones in
Human PlacentaProcessedfor Encapsulationand Consumption, 43 PLACENTA 86, 86
(2016) [hereinafter Young, 17 Hormones in Human Placenta].
10. Sarah Bunton, 11 Celebrities Who Ate Their Placenta& Are Happy to Admit
It, ROMPER (July 6, 2016), https://www.romper.com/p/11-celebrities-who-ate-theirplacenta-are-happy-to-admit-it-13659; Mikaela Conley, Mad Mom? January Jones
Eats Her Own Placenta, ABC NEWS (Mar. 26, 2012), http://abcnews.go.com/
blogs/healthl2012/03/26/mad-mom-january-jones-eats-her-own-placenta/;
Jamieson
Cox, Kim Kardashian's Placenta Convinced Me to Subscribe to Her App, VERGE
(Dec. 14, 2015, 4:50 PM), https://www.theverge.com/2015/12/14/10123898/kim-kard
ashian-app-subscription-eating-placenta.
11. Tara Haelle, PlacentaPills Gain Fans Among New Moms, but Benefits Are
Elusive, NPR (June 4, 2015), http://www.npr.org/sections/health-shots/2015/06/04/
411990944/placenta-pills-gain-fans-among-new-moms-but-benefit s-are-elusive; Peter
Holley, Her Newborn Kept Getting Sick Because She Was Ingesting Placenta, CDC
Says, WASH. POST (June 30, 2017), https://www.washingtonpost.com/news/to-yourhealth/wp/2017/0 6 / 3 0/her-newborn-kept-getting-sick-because-she-was-ingesting-plac
enta-cdc-says/?utm term=.b8906809dl20; Ellen McCarthy, 'Are You Going to Eat
That?' When It Comes to Placenta, the Answer Is Increasingly 'Yes, WASH. POST
(Aug. 5, 2014), https://www.wash ingtonpost.comlifestyle/style/are-you-going-to-eat-
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"dramatic rise in women choosing to ingest their placentas after
giving birth," 12 and has called placentophagy "mainstream in recent
years." 13
A study published in the Journal of Alternative and
Complementary Medicine found that two-thirds of female patients
14
were familiar with placentophagy, as were 89% of providers. Twenty
percent of the surveyed patients knew someone who had consumed
her placenta. 15 Women with a household income greater than
$100,000 and with higher education were more likely to have heard of
placentophagy and be willing to try it.16 A similar study of both male
and female college students also found that two-thirds of participants
knew about placentophagy and more than 25% would consider it
themselves. 17 The practice is now so commonplace that 66% of
hospitals have protocols in place allowing the placenta's release from
the hospital.1 8 Some states, like Hawaii, Oregon, Texas, and
Massachusetts, have created a statutory right to the placenta after
birth.19 And in Mississippi, a woman successfully sued to have the

that-when-it-comes-to-placenta-the-answer-is-increasingly-yes/2014/ 08/05/0022c596180b-11e4-9e3b-7f2f110c6265story.html?utm term=.9041f92a8655; Nancy Redd, I
PM),
9:13
2012,
(Mar. 25,
Placenta, N.Y. TIMES
Regret Eating My
https://parenting.blogs.nytimes.com/2012/03/25/i-regret-eating-my-placenta/; Olga
Oksman, Eating Your Placenta-Is It Healthy or Just Weird?, GUARDIAN (Feb. 10,
2016, 14:05 EST), https://www.theguardian.com/1ifeandstyle/2016/feb/10/eating-yourplacenta-healthy-motherhood-new-mothers-infants-postpartim-depression-placentop
hagy-fda.
McCarthy, supra note 11.
12.
Holley, supra note 11.
13.
Schuette et al., supra note 2, at 60. The study surveyed women at two
14.
women's health practices in Chicago and healthcare providers operating out of
hospitals in three different urban settings.
Id. at 62.
15.
Id.
16.
Gwendolyn E. Cremers & Kathryn G. Low, Attitudes Toward Placentophagy:
17.
A Brief Report, 35 HEALTH CARE FOR WOMEN INTL 113, 117 (2014).
In one study, 66.7% of hospitals had a policy for the release of placentas from
18.
the institution. Baergen et al., supra note 1, at 327-28; see also Hayes, supra note 2,
at 86; Joseph et al., supra note 2, at 481; McCarthy, supra note 11 ("Katherine Himes,
a doctor of maternal fetal medicine at the University of Pittsburgh Medical Center,
has had so many patients come to her with questions about placentas that the hospital
developed a protocol for those who wish to take their placentas home."); Schuette et
al., supra note 2, at 63.
See, e.g., Hayes, supra note 2, at 86 ("Laws regulating infectious waste in
19.
Hawaii, Oregon, and most recently Texas explicitly allow mothers to take their
placentas home from the hospital" and "[i]nfectious waste handling and disposal laws
in other states neither allow nor prohibit women from taking their placentas
home . . . ."); Memorandum from Lauren Smith, Medical Director and Chief Medical
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placenta removed from the state's list of medical waste that was not
permitted to leave the hospital.20 Mississippi now "legalizes placental
release upon request." 2 1

Placentophagy can take many forms. Some women cook and eat
the placenta like meat, while others mix it raw into smoothies or other
edibles. 22 The vast majority of women, however, pay placentophagy
providers to pick up the placenta from the hospital, dehydrate it, grind
it, and place it into capsules that can be swallowed as pills during
their first month's post-partum. 23 The placenta is typically heated
during processing to kill any bacteria that may be on the organ. 24
Placentophagy providers can process the placenta at their own
homes, 25 at a processing site,26 or at the mother's house. 27 The price of
the service often includes other placenta-based products, such as
placenta tinctures-raw placenta steeped in alcohol-placenta soaps,
and placenta lotions. 28 The average cost is between $150 and $200.29
Almost all placentophagy providers are women, working either as
sole practitioners or in collaboration with other women. 30 Many
providers have been consumers themselves and were motivated to
start their businesses to help other mothers experience the same

Officer, to Hospital CEOs (Oct. 25, 2010), available at http://www.mass.gov/
eohhs/docs/dphlenvironmental/sanitation/placenta-guidance.pdt
20.
Farr et al., supra note 2, at 407.
21. Id.
22.
Coyle et al., supra note 2, at 674-75; Joseph et al., supra note 2, at 478;
McCarthy, supra note 11.
23. In one survey, between 70-80% of women chose encapsulation. Hayes, supra
note 2, at 80.
24.
Selander et al., supra note 8, at 95.

25.

See Questions to Ask Before Hiring Your PlacentaEncapsulationSpecialist,

FIND PLACENTA ENCAPSULATION, http://fndplacentaencapsulation.com/questions-to-

ask-before-hiring-your-placenta-encapsulation-specialist/ (last visited Mar. 25, 2019)
("Some specialists ... prepare the placenta in their home kitchen.").
26.

See, e.g., Services, PLACENTA ENCAPSULATION KC, http://www.placenta

encapsulationkc.com/services (last visited Mar. 25, 2019).
27. See, e.g., The PlacentaLady Experience, PLACENTA LADY, http://www.place
ntalady.comlexperience (last visited Mar. 25, 2019).
28. See, e.g., Services, supra note 26; Valerie Rosas and Henry Garcia, FIND
PLACENTA

ENCAPSULATION,

http://findplacentaencapsulation.com/placenta-special

ist-directory/valerie-rosas/ (last visited Mar. 25, 2019).
29. See, e.g., Joseph et al., supra note 2, at 481-82.
30. Almost all of the 748 placentophagy providers listed on the Placenta
Encapsulation website are women. Find a Placenta Specialist, FIND PLACENTA
ENCAPSULATION,
http://findplacentaencapsulation.com/find-a-placenta-specialist/
(last visited Mar. 25, 2019).
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benefits they experienced. 3 1 As a result, women are almost exclusively
the providers and consumers of placentophagy.
Women engage in placentophagy for a variety of perceived
benefits. First among them is the belief that consuming one's placenta
will combat the onset of symptoms of post-partum depression or the
less severe "baby blues." 3 2 Fifty percent of placentophagy users were
motivated to purchase encapsulated placenta because they had
previously experienced a postnatal mood disorder after at least one of
33
Other women consume their placentas
their former pregnancies.
seeking to increase their breast milk supply, reduce post-partum pain
or bleeding, improve energy, or replenish depleted nutrients and
hormones. 34 For many, placentophagy is a rejection of what they
perceive as the "patriarchal medicalization of birth that has given
35
Instead, these women
medicine power over women's bodies."
typically gravitate toward a female-centered birthing approach that
36
treats childbirth as empowering.
The anecdotal evidence is overwhelmingly positive. The only
published study to survey placentophagy users found that 95% of
women who had engaged in placentophagy had a positive experience
37
and 98% stated that they would do it again for subsequent births.
More specifically, 40% of women reported feeling an improved mood,
26% reported increased energy, 15% reported improved lactation, and
38
7% reported alleviated bleeding.
It is not difficult to understand why the practice has grown in
popularity. A woman's first months post-partum are often filled with
physical pain and emotional tumult-women report feeling breast,
vaginal, or cesarean pain, urinary incontinence, hemorrhoids, hair

ENCAPSULATION,
PLACENTA
FIND
Rebolo,
Amelia
e.g.,
See,
31.
http://findplacentaencapsulation.com/placenta-specialist-directory/amelia-rebolo/
(last visited Mar. 25, 2019).
Schuette et al., supra note 2, at 64 ("Perhaps our most significant finding
32.
was that mothers with a history of a postpartum mood disorder were more willing to
try placentophagy in place of prescription medication than women with no prior
mental health issues."); Selander et al., supra note 8, at 102-03;
Selander et al., supra note 8, at 102.
33.
34. Id.
Elizabeth Dickinson, et al., Empowering Disgust: Redefining Alternative
35.
Postpartum Placenta Practices, 40 WOMEN'S STUD. COMM. 111, 123 (2017); see also
Section IIA.
Dickinson et al., supra note 35, at 124.
36.
Selander et al., supra note 8, at 105. But see Redd, supra note 11.
37.
Selander et al., supra note 8, at 105.
38.
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loss, anxiety, and severe mood swings. 39 Twenty percent of women
experience post-partum depression4O and up to 80% suffer from a
short-term, less severe post-partum mood disorder colloquially
referred to as the baby blues. 41 Women frequently feel disappointed
that their physicians did not prepare them for these post-partum
symptoms, focusing instead on pregnancy and birth. 42 Furthermore,
these symptoms come at a time when women are no longer in as
regular contact with their healthcare providers. 43 And "[p]roviders are
often hesitant to prescribe medication to breast-feeding women
because of concerns regarding untoward effects on the infant." 44 Also
out of concern for their breastfeeding infants, "postpartum women are
more likely to prefer nonpharmacologic treatment methods for
depression."45 As a result, when women are facing the real and
challenging struggles after giving birth, they may also lack continuity
of care and feel personal or external pressure to avoid
pharmaceuticals that might improve their physical or emotional
symptoms. Placentophagy gives women a mechanism to improve
these symptoms without the barriers existing in the medical system
or the concerns associated with pharmaceuticals, whether or not those
concerns are warranted. 46

Despite the perceived benefits ofplacentophagy, there is very little
scientific evidence demonstrating the health effects that women
anecdotally experience. Scientific theories exist to explain the
perceived benefits, 47 and research in animals has demonstrated that

&

39.
Elizabeth A. Howell, Lack of PatientPreparationfor the PostpartumPeriod
and Patients' Satisfaction with Their Obstetric Clinicians, 115 OBSTETRICS
GYNECOLOGY 284, 285 (2010).
40.
Schuette et al., supra note 2, at 61.
41.
The baby blues are a less severe, short-term form of post-partum depression.
Baby Blues, AM. PREGNANCY ASS'N, http://americanpregnancy.org/first-year-oflifelbaby-blues/ (last updated Aug. 2015).
42.
Anika Martin et al., Views of Women and Clinicians on Postpartum
Preparationand Recovery, 18 MATERNAL CHILD HEALTH J. 707, 709-10 (2014); Baby
Blues, supra note 41.
43.
Martin et al., supra note 42, at 710.
44.
Schuette et al., supra note 2, at 61.
45.
Id.
46.
The recommendation to avoid drugs during pregnancy and lactation may not
always be in the best interest of the mother or the child and can reflect the government
or provider's preference to protect the child from unknown risks over the mother's
known pain. See, e.g., Greer Donley, EncouragingMaternalSacrifice:How Regulations
Governing the Consumption of PharmaceuticalsDuring Pregnancy Prioritize Fetal
Safety over MaternalHealth and Autonomy, 39 N.Y.U. REV. L. & Soc. CHANGE 45, 47
(2015).
47.
See, e.g., Joseph et al., supra note 2, at 479-80; Marraccini & Gorman, supra
note 2 at 375-76.
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consumed placenta may be effective at reducing pain, increasing
lactation, and replenishing hormones in animals, though it is unclear
8
whether this data can be extrapolated to humans.4 Supporters also
49
point to the fact that nearly all mammals eat their placenta, and
that Chinese medicine has treated various disorders with dried
50
human placenta for centuries.
51
But studies in humans have not demonstrated benefits. For
instance, one theory to explain the placenta's positive effect is that it
replaces key nutrients and hormones that were depleted during the
birthing process. 5 2 But one study that analyzed the nutrients in a
daily dosage of encapsulated placenta found that it only contained
53
25% of the daily-recommended iron intake for lactating women.
54
Other nutrients were even less prominent. Another study analyzing
the concentrations of hormones in encapsulated placenta found that
only three of seventeen hormones were concentrated enough to have
55
even the possibility of a therapeutic effect. When a double-blind,
hormone
salivary
the
evaluated
trial
placebo-controlled
concentrations of post-partum women who consumed their placentas.
56
verses placebo, it found no statistically significant difference. The
same trial found no statistically significant difference in depressive
symptoms between those women who ingested placebo and those who
ingested placenta over the entire post-partum period, though it did
report preliminary findings that the placenta group was less fatigued
57
and had less depressive symptoms in the first week post-partum.
Finally, a placebo-controlled study found that encapsulated placenta
did not improve post-partum iron status as compared to a placebo of
58
dehydrated beef, despite containing higher concentrations of iron.
Taken together, the evidence suggests that the benefits of

Coyle et al., supra note 2, at 675-77.
48.
Hayes, supra note 2, at 79; Marraccini & Gorman, supra note 2 at 372.
49.
Coyle et al., supra note 2, at 674.
50.
Id. ("Despite the amount of information available to the public on the
51.
therapeutic benefits of placentophagy, there is no scientific evidence examining its
effects in humans, and the data from animals are inconclusive.").
Marraccini & Gorman, supra note 2, at 375-76.
52.
Sharon M. Young et al., Human Placenta Processed for Encapsulation
53.
Contains Modest Concentrationsof 14 Trace Minerals and Elements, 36 NUTRITION
RES. 872, 876 (2016) [hereinafter Young, 14 Trace Minerals].
Id. at 877.
54.
Young, 17 Hormones in Human Placenta,supra note 9, at 88-89.
55.
Sharon M. Young et al., Effects of Placentophagy on Maternal Salivary
56.
Hormones: A Pilot Trial, Part 1, 31 WOMEN & BIRTH e245, e245 (2017) [hereinafter
Young, Pilot 1].
Young, Pilot 2, supra note 2, at 258.
57.
Gryder et al., supra note 2, at 74, 77.
58.
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placentophagy may be largely attributed to the placebo effect.59 Of
course, the placebo effect can be very powerful, causing improvements
on its own, 60 and some women still advocate for access to placenta pills
even under the assumption that the benefits derive primarily from
placebo.6 1
The unclear benefits of placentophagy must be balanced against
possible risks. One initial concern is that women with serious
depression might forgo needed anti-depressants and face a mental
health crisis if placentophagy is not effective. 62 Opponents also raise
concerns about the safety of the practice even among relatively
healthy mothers. For instance, because the placenta functions to filter
out toxins, some have theorized that those toxins could be present in
encapsulated placenta and harmful to consume. 6 3 Another risk is the
potential adverse effect of bacteria or viruses that grow on the
placental tissue when it is not properly handled.64 This concern is
especially prominent in light of an announcement by the Centers for
Disease Control reporting that an infant contracted a bacterial
infection that was passed through its mother's breast milk after she
consumed encapsulated placenta.6 5 The infant was hospitalized twice
before the cause of the infection was discovered.6 6 Opponents are also
concerned with the transmission of disease if multiple placentas are
processed at the same site without proper sanitation procedures. Even
worse, placentophagy providers can intentionally cross-contaminate a
woman's pills. One egregious example of this occurred in 2008 when
FDA raided a placentophagy site in Miami that was accused of
making large batches of placenta pills by mixing as many as fifteen

59.
Coyle et al., supra note 2, at 678 ("Reports of human benefit may, at least
partially, be a result of placebo effects . . . .").
60.
The Power of the Placebo Effect, HARV. HEALTH PUB. (May 2017),
httpsi//www.health.harvard.edulmental-health/the-power-of-the-placebo-effect.
61.
Dickinson et al., supra note 35, at 122 (quoting a supporter as articulating
the following sentiment: "Even if it is a placebo effect, placebo is powerful. If it can
possibly help, I don't have a problem trying it. Let's give it a shot." And noting that
"the lack of medical research [here] is not an issue. If it 'can't hurt,' and if it may just
help, supporters make a leap of faith to try.").
62.
See generally Nicholas Bakalar, Science Fails to See Benefits of Eating
Placenta, N.Y. TIMES (June 9, 2015, 1:33 PM), https://well.blogs.nytimes.com/
2015/06/09/science-fails-to-see-benefits-of-eating-placenta/?r-1.
63.
Coyle et al., supra note 2, at 674.
64. Id.
65.
Genevieve L. Buser et al., Notes from the Field: Late-Onset Infant Group B
Streptococcus Infection Associated with Maternal Consumptionof CapsulesContaining
DehydratedPlacenta-Oregon,2016, CENTERS FOR DISEASE CONTROL & PREVENTION
677 (June 30, 2017), https://www.cde.gov/mmwr/volumes/66/wr/mm6625a4.htm.
66.
Id.
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placentas together without telling the mothers that their placenta
67
pills contained other women's placentas.
These concerns are well taken, but largely focus on the risks
associated with bad practices. There is little to no evidence that
encapsulated placenta is unsafe when processed properly. One study
explored the theory that the placenta may contain toxins that are
harmful to consume; it found that, to the extent that any toxins were
present, their concentrations were negligible and did not render the
placenta unsafe. 68 Another study found that although "[p]otentially
pathogenic organisms (E. coli, Gardnerella vaginalis) were detected
in raw placental tissue[, they] were absent after dehydration," which
69
exposes the placenta to high heat. It also confirmed that dehydrated
70
placenta lacked any toxic elements. With regard to the CDC report,
placentophagy advocates were quick to highlight that CDC's
description of how the placenta was prepared made clear that the
provider did not properly cook and dehydrate the tissue to kill
bacteria.7 1 Some researchers, including the CDC's own report, have
supported this hypothesis, while others have argued that even if poor
practices were not to blame, one case study should not outweigh
72
strong evidence of safety elsewhere. Many placentophagy providers
FloridaDepartment of Health Joint Investigation Leads to Federal Search
67.
Warrant in Miami, WCTV (Dec. 31, 2008, 3:55 PM), http://www.wetv.tv/homel
headlines/36945319.html [hereinafter FloridaDepartmentof Health].
68. Young, 14 Trace Minerals, supra note 53, at 877. The study was careful to
note that an individual mother's exposure to toxins-for instance, a woman who
smoked during her pregnancy-may cause her specific placenta to contain more
contaminates than the placentas the study examined. Id. at 873.
Sophia K. Johnson et al., Human Placentophagy:Effects of Dehydrationand
69.
Steaming on Hormones, Metals and Bacteria in Placental Tissue, 67 PLACENTA 8, 11

.

(2018).
70. Id. at 8 ("According to regulations of the European Union the concentrations
of potentially toxic elements (As, Cd, Hg, Pb) were below the toxicity threshold for
foodstuffs.").
See, e.g., Jodi Selander, Can I Get Group B Strep from Placenta Capsules?,
71.
PLACENTA BENEFITS (June 29, 2017), https-//placentabenefits.info/group-b-strep0
from-placenta-capsules/ ("Per the article, heating at 130 F (54C) for 121 minutes is
That did not happen in this
tissue.
placental
the
required to reduce bacteria present in
case."); Is Encapsulation Ok When I Am GBS+?, ST. LOUIS PLACENTA LADY,
https://stlplacentalady.weebly.com/what-about-gbs.html (last visited Mar. 25, 2019)
("It is suspected that the family in Portland, OR, did not prepare their placenta at
temperatures high enough to kill the strep bacteria and possibly passed on infection
from their capsules to the baby.").
Daniel C. Benyshek et al., Reply Letter to the Editor, PlacentophagyAmong
72.
Women PlanningCommunity Births in the United States: Frequency, Rationale, and
Associated Neonatal Outcomes, BIRTH (2018), https://onhlinelibrary.wiley.coml/
doi/full/10.1111fbirt.12381 ("Epidemiology best practices would suggest that a single
case study is insufficient evidence from which to extend a clinical recommendation.
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have themselves created manuals, guidelines, and even certification
programs, which describe proper processing procedures designed to
specifically prevent incidents like this one. 7 3 The certification
programs, for instance, include required trainings on proper food
handling and blood-borne pathogens. 74 Placentophagy studies
involving human subjects have not reported any adverse events
among the participants, 75 and the use of dried human placenta in
Chinese medicine supports a history of safe use.76 Research has also

demonstrated that the babies of women who consume their placentas
do not fare any worse than those of women who do not. 77

Furthermore, regulation could mitigate many of the risks
associated with bad practices and lead to a safer product. But FDA
has thus far "adopted a hands-off policy."7 8 This might be, at least in
part, due to the difficulty in classifying the product under one of FDA's
categories. For instance, one placentophagy provider documented her
experience contacting FDA about the regulatory requirements for her

. . On the contrary, our medical records-based study of more than 7000 placenta
consumers, with a control group of over 10 000 non-consumers, found no evidence of

harm to the neonate."); Farr et al., supra note 2, at 405 ("The CDC hypothesized that
heating for a sufficient time at a temperature adequate to decrease GBS bacterial
counts might not have been carried out in this case. Their idea is supported by studies
that report the presence of a unique low-abundance microbiome in the healthy human
placenta.").
73. Hayes, supra note 2, at 83.
74.
See e.g., Get Certified, ASS'N PLACENTA PREPARATION ARTS,
https://placentaassociation.com/placenta-certif]cation/ (last visited Mar. 25, 2019);
Placenta Encapsulation Training, INT'L PLACENTA & POST-PARTUM Ass'N,
https://www.ippatraining.com/placenta-encapsulation (last visited Mar. 25, 2019).
75. Gryder et al., supra note 2, at 68; Selander et al., supranote 8, at 109; Young,
Pilot 1, supra note 56, at e255; Young, Pilot 2, supra note 2, at e267-68. In fact, the
only participant to drop out due to an adverse event in Sharon Young's pilot trial was
a subject assigned to the placebo group. Young, Pilot 1, supra note 56, at e249.
76. Coyle et al., supra note 2, at 674.
77. Daniel C. Benyshek et al., Placentophagy Among Women Planning
Community Births in the United States: Frequency, Rationale, and Associated
Neonatal Outcomes, 45 BIRTH 459, 466 (2018), https://onlinelibrary.wiley.com/doilabs/
10.1111/birt. 12375. Alex Farr and colleagues criticized the scientific methods used in
the study in a letter to the editor, to which the research team responded. Alex Farr et
al., Letter to the Editor, PlacentophagyAmong Women PlanningCommunity Births in
the United States: Frequency, Rationale, and Associated Neonatal Outcomes, BIRTH
(2018), https://onlinelibrary.wiley.com/doilepdf/10. 111 1/birt. 12375.
78. Michael McLaughlin, PlacentaPill Makers Turn Afterbirth into Nutritional
Supplement for New
Moms, HUFFPOST (July 20,
2011,
7:54
AM),
https://www.huffingtonpost.com/2011/07/20/placenta-pill-maker-nutritional-supplem
ent n_ 886420.html.
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product.7 9 She described being "passed from one department to
another."8 0 Eventually, FDA told her that because she was "working
with human tissue, [her] activities would have to be regulated by the
FDA."81 This suggests that FDA concluded that the product should be
regulated as a human tissue, but FDA never followed up with the
provider directly to give guidance. And to the contrary, it later told
USA Today that the provider's website contained unsubstantiated
disease claims-an indication that FDA considered her product a
supplement, not a human tissue. 8 2 FDA has thus far never instigated
a warning letter or enforcement action against an encapsulated
placenta provider, nor has it provided any official guidance on the
practice.
FDA's hands-off approach has left the practice largely
unregulated by the federal government; states, too, provide little
guidance. 83 As the practice grows and the risks of improper processing
are exposed, the agency must consider whether and how to regulate
encapsulated placenta. 84 Part II explores the different categories

Jodi Selander, FDA Regulation, PLACENTA BENEFITS (Aug. 29, 2007),
79.
http://placentabenefits.info/fda-regulation/.
Id.
80.
Id.
81.
82. Id.; Steve Friess, Ingesting the Placenta:Is it Healthy for New Moms?, USA
TODAY (July 24, 2007), https://www.buffalo.edulcontent/dam/www/news/importedl/
pdflJuly07fUSATodayKristalPlacenta.pdf.
Bakalar, supra note 62 ('"This is an unregulated practice with no evidence83.
based research about its risks and benefits."'); Farr et al., supra note 2, at 406 ("Most
states in the United States lack clear regulations and safety guidelines that address
placentophagy. As a result, current health policy at the state level appears to allow
placental release and consumption, under the general rule that what is not explicitly
prohibited is permitted."); Marla Paul, Eating the Placenta: Trendy but No Proven
Health Benefits and Unknown Risks, NORTHWESTERN NEWS (June 4, 2015),
https://news.northwestern.edulstories/2015/06/eating-the-placenta-trendy-but-no-pro
ven-health-benefits-and-unknown -risks-- ('"There are no regulations as to how the
placenta is stored and prepared, and the dosing is inconsistent,' Coyle said. 'Women
really don't know what they are ingesting."'). This Article concerns FDA regulation of
encapsulated placenta; state regulation is beyond its scope.
84. This analysis will require FDA to contemplate whether state regulation, to
the extent it exists at all, is sufficient to protect women. Certain states have laws that
may apply to placentophagy. In New York, individuals that work with human tissues
must get a license. See McLaughlin, supra note 78. But a New York Health
Department official stated that no placentophagy provider has ever applied for a
license. Id. This is despite the fact that numerous placentophagy providers operate in
the state and are unaware of the regulations. Id.; see also Placenta Service Provider
Directory, New York, AVOID BABY BLUES, http://www.avoidthebabyblues.com/ newyork.html (last visited Mar. 25, 2019). The Southern Nevada Health District will not
license any facility to process placenta for human consumption, which is why
placentophagy providers in the state typically work in the mother's kitchen.
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under which encapsulated placenta could be regulated, providing the
background landscape that underlies FDA's regulatory decisions. It
explains how encapsulated placenta could meet the definition of a
drug, supplement, or human tissue, as well as the general regulatory
requirements that manufacturers within each category must meet.
Although FDA has a mechanism for sorting products that meet
multiple definitions, I explain below that its approach might not
provide a clear result in this context.
II. ENCAPSULATED PLACENTA: DRUG, SUPPLEMENT, OR HUMAN
TISSUE?
FDA is responsible for "protecting the public health" by regulating
drugs, biological products, devices, food, cosmetics, radiation-emitting
products, and tobacco products.8 5 Its regulatory authority stems from
the federal Food, Drug, and Cosmetic Act ("FDCA").86 Pursuant to the
FDCA, FDA utilizes a category-based regulatory structure, whereby
the category under which a product falls determines how the agency
regulates it.87 The regulatory burdens can be extensive or negligible
depending on the category, impacting how accessible the product is to
the public. I explain below that placenta products could meet the
definition of drug, supplement, or human tissue and are therefore
subject to FDA regulation under the FDCA.88 These three regulatory

Frequently Asked Questions, PLACENTA LADY, http://www.placentalady.com/faq (last
visited Mar. 25, 2019).
85.
What We Do, FOOD & DRUG ADMIN., https://www.fda.gov/AboutFDA/
WhatWeDo/default.htm (last visited Mar. 25, 2019).
86. Federal Food, Drug, and Cosmetic Act (FD&C Act), FOOD & DRUG ADMIN.,
https://www.fda.gov/Regulatory
Information/LawsEnforcedbyFDA/FederalFoodDrugandCosmeticActFDCAct/default.
htm (last updated Apr. 21, 2017); What Does FDA Regulate?, FOOD & DRUG ADMIN.,
https://www.fda.gov/AboutFDA/Transparency/Basics/ucml94879.htm
(last visited
Mar. 25, 2019).
87.
What Does FDA Regulate?, supranote 86.
88. Although the product is primarily sold in intrastate commerce, FDA retains
regulatory authority. In Regenerative Sciences, the D.C. Circuit found that FDA had
the authority to regulate a purely intrastate product to treat orthopedic injuries.
United States v. Regenerative Scis., LLC, 741 F.3d 1314, 1317 (D.C. Cir. 2014). The
procedure involved providers in Colorado extracting mesenchymal stem cells from a
patient's bone marrow, mixing the stem cells with culturing agents and an antibiotic,
and then injecting the solution back into the patients. Id. at 1318. The mixture FDA
sought to regulate in RegenerativeSciences is very similar to encapsulated placenta in
that both contain a processed form of the individual's extracted tissue or fluid that was
transferred back into individual donor. Encapsulated placenta, however, is less
processed as it does not contain other ingredients like the mixture in Regenerative
Sciences. The Court held that because the procedure would "undoubtedly have effects
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for
burdens
regulatory
different
wildly
involve
schemes
typically
FDA
how
manufacturers. Later in this section, I describe
categorizes products that meet multiple categories, but note that FDA
has never explicitly categorized a product like encapsulated placenta.
Accordingly, it is unclear how the agency might regulate it.
A. The Definitions and Regulatory Requirements for Drugs,
Supplements, and Human Tissues
Encapsulated placenta could meet the definition of a drug,
supplement, or human tissue. Of these three categories, drugs are
regulated the most intensely and supplements, the least intensely. As
you will see below, each regulatory category aims to prevent different
kinds of harms. Drug regulation fundamentally aims to protect
consumers from the risks of unsafe or ineffective novel treatments for
disease. The supplement regulations, by contrast, regulate products
that are not intended to treat disease, but to supplement the diet; they
are therefore aimed at preventing manufacturers from marketing
their products with disease claims that the manufacturer did not
prove through the rigorous drug approval process. The human tissue
regulations are bifurcated. Some human tissue products are regulated
as drugs, while other less-risky products are regulated only according
to a subset of regulations that are primarily aimed at stopping the
spread of communicable disease. The discussion below highlights how
encapsulated placenta's categorization will dramatically impact not
only the product's availability and price, but also the amount of
information we have about its safety and effectiveness.
1. Drugs: Premarket Review for Safety and Effectiveness
FDA defines a drug as a "tablet, capsule, or solution, that contains
a drug substance," which is defined as an ingredient intended for use
"in the diagnosis, cure, mitigation, treatment, or prevention of disease

on interstate markets for orthopedic care" and one ingredient of the mixture was
shipped in interstate commerce, "[t]he Commerce Clause poses no obstacle to
regulating the Mixture under the FDCA." Id. at 1320. The D.C. Circuit was also
unwilling to accept the providers' argument that their product was not regulated by
the FDCA because the statute itself only prohibits interstate conduct, like shipping a
misbranded or adulterated product through interstate commerce. Id. The First and
Ninth Circuits have held similarly. Baker v. United States, 932 F.2d 813, 814 (9th Cir.
1991); United States v. Dianovin Pharm., Inc., 475 F.2d 100, 102-03 (1st Cir. 1973).
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or to affect the structure or any function of the human body."89 Drugs
that are created out of human cells and tissues are called biological
products or biologics-a subset within the drug category that has its
own requirements, but must also undergo premarket review.90
Encapsulated placenta could meet this definition. It is a capsule
containing an ingredient that certain manufacturers intend to
mitigate, treat, and prevent post-partum diseases, like depression,
mood disorders, and anemia.
Drugs are held to the highest standard of FDA review. Drugs,
including biologics, may not be sold or marketed until they have
successfully completed the rigorous FDA premarket approval
process.9 1 This process requires the drug manufacturers to provegenerally through multiple phases of double-blind, placebo-controlled
studies-that their product is both safe and effective. 92 Drug
companies must first demonstrate safety and efficacy in animal
studies before completing three phases of human trials, each
requiring extensive ethics and scientific review.93 It can take over a
decade, and cost tens of millions of dollars, to build the evidentiary
support to obtain FDA approval.9 4 And of course, it is not always
successful; if the results reveal at any point in the process that the
drug is not safe or effective, the drug will be denied approval and the
manufacturer's investment will be wasted. Only about one in six
drugs that enter the first phase of clinical trials obtain FDA's
approval, underscoring how difficult and expensive FDA regulations

89.
21 C.F.R. § 314.3(b) (2017); see also Drugs@FDA Glossary of Terms, FOOD&
DRUG ADMIN., https://www.fda.gov/drugs/informationondrugs/ucm079436.htm (last
visited Mar. 25, 2019).
90.
Drugs@FDA Glossary of Terms, supra note 89.
91.
Development & Approval Process (Drugs), FOOD & DRUG ADMIN.,
https://www.fda.gov/drugs/developmentapprovalprocess/default.htm (last visited Apr.
3, 2019).
92.
Greer Donley, A System of Men and Not of Laws: What Due Process Tells Us
About the Deficiencies in InstitutionalReview Boards, 7 NW. INTERDISC. L. REV. 197,
215-16 (2014); Drug Study Designs-Information Sheet, FOOD & DRUG ADMIN.,
https://www.fda.gov/RegulatoryInformation/Guidances/ucml26501.htm
(last visited
Mar. 25, 2019); The FDA's Drug Review Process: Ensuring Drugs Are Safe and
Effective, FOOD & DRUG ADMIN., https://www.fda.gov/drugs/resourcesforyou/con
sumers/ucm143534.htm (last visited Mar. 25, 2019) [hereinafter The FDA's Drug
Review Process].
93.
Donley, supra note 46, at 49-51; The FDA's DrugReview Process,supra note
92.
94.
Donley, supra note 46, at 49-51; Aylin Sertkaya et al., Key Cost Drivers of
PharmaceuticalClinical Trials in the United States, 13 CLINICAL TRIALS 117, 117, 120
(2016) (showing that the average cost of a Phase III clinical trial alone was
$11.5 million to $52.9 million).
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make drug development.9 5 This extensive burden, however, is
justified by the serious harms posed by unregulated drugs, the
public's need for research on the drug's benefits and risks, and the
financial advantages these companies enjoy if their product is
approved. Unlike supplements, which typically have a history of safe
use,96 new drugs involve ingredients that have never been consumed
by humans and the effects are therefore entirely unknown.
Perhaps the most important advantage FDA grants drug
manufacturers is five years of regulatory exclusivity "for new chemical
entities not previously approved by the FDA."97 Exclusivity gives drug
manufacturers a short-term monopoly to incentivize innovation and
allow them to recoup the money invested in the drug's development
and approval. 98 Regulatory exclusivity runs concurrently with patent
protection, but often lasts longer for drugs whose patents expire while
the manufacturer was conducting the research necessary for FDA
approval.99 In the years of market exclusivity, the manufacturer can
make billions of dollars from the benefits of its monopoly, which
100
And perhaps equally
include the ability to hike up drug prices.
important to manufacturers is the fact that insurance companies pay
for prescription FDA-approved drugs, which can also dramatically
increase the price manufacturers can charge; by comparison,
consumers generally pay for supplements out of pocket, which forces
manufacturers to keep prices down or lose customers.

Rebecca Dresser, The 'Right to Try" Investigational Drugs: Science and
95.
Stories in the Access Debate, 93 TEX. L. REV. 1631, 1635 (2015).
Supplements must have either been marketed for at least thirty years or be
96.
currently in the food supply; if not, they must obtain new dietary ingredient approval.
21 U.S.C. § 350b(d) (2011); 21 U.S.C. § 350b(a)(1) (2011); FOOD & DRUG ADMIN.,
DIETARY SUPPLEMENTS: NEW DIETARY INGREDIENT NOTIFICATIONS AND RELATED
ISSUES: GUIDANCE FOR INDUSTRY 10, 13 (2016), https://www.fda.gov/downloads/
Food/GuidanceRegulation/GuidanceDocumentsRegulatory
Information/UCM515733.pdf [hereinafter FDA, DIETARY SUPPLEMENTS].
Rebecca S. Eisenberg, The Role of the FDA in Innovation Policy, 13 MICH.
97.
TELECOMM. & TECH. L. REV. 345, 359-60 (2007) (citing 21 U.S.C. § 355(j)(5)(F)(ii-iii)).
FDA also provides three years of market exclusivity for products that make "changes
in a previously approved product that required conducting new clinical trials to win
FDA approval." Id.
Id. at 361. There is big caveat, however, for products that are widely
98.
available before obtaining FDA approval: FDA must choose to enforce the exclusivity.
See infra notes 117, 267.
Eisenerg, supra note 97, at 360.
99.
Kate Greenwood, The Mysteries of Pregnancy:The Role of Law in Solving the
100.
Problemof Unknown but Knowable Maternal-FetalMedicationRisk, 79 U. CIN. L. REV.
267, 313-14 (2011) (explaining that just six months of exclusivity can lead to hundreds
of millions of dollars); Donley, supra note 46, at 85-87.
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Another benefit of premarket approval is that manufacturers may
market their product as safe and effective at treating, preventing, or
mitigating the disease or condition for which it was approved ("disease
claims"). Disease claims are special, and only drug manufacturers are
allowed to make them--only they have produced the research
necessary to prove efficacy.101 Drug manufacturers are nevertheless
still prohibited from marketing their drug as effective at treating a
condition for which the drug was not approved, even though
physicians can prescribe drugs for unapproved or "off-label" uses. 102
But as explored below, encapsulated placenta manufacturers do not
stand to benefit from exclusivity as typical drug manufacturers; as a
result, classification as a drug would come with few benefits and
enormous costs.
2. Supplements: Enter the Market Directly
Encapsulated placenta could also fit within the definition of a
dietary supplement. FDA defines a dietary supplement as a product
intended for ingestion that contains a "dietary ingredient" intended to
add further nutritional value to or otherwise supplement the diet.1 03
Dietary ingredients include, for instance, vitamins, minerals, and
amino acids. 104 Supplements can be tablets, capsules, powders, energy
bars, and liquids.10 5 Encapsulated placenta contains numerous
vitamins-including iron, manganese, rubidium, selenium, and
zinc-and therefore could meet the definition of a supplement.1 06
Supplements are regulated very differently from drugs, which
require FDA approval before entering the market. Instead, most
supplements enter the market directly without any FDA approval. 0 7

101.

See infra Section IV.B.1.

102.
FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: RESPONDING TO
UNSOLICITED REQUESTS FOR OFF-LABEL INFORMATION ABOUT PRESCRIPTION DRUGS
AND
MEDICAL
DEVICES
2
(2011),
https://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/UCM285145.pdf (noting that
it "generally violate[s] the law" when a manufacturer introduces a product into
commerce for an intended use that has not been FDA approved, but it is legal for a
physician to proscribe the drug for an unapproved use).
103.
FDA 101: Dietary Supplements, FOOD & DRUG ADMIN., https://www.fda.gov/
ForConsumers/ConsumerUpdates/ ucm050803.htm (last visited Mar. 25, 2019).
104. Id. ("Dietary ingredients include vitamins, minerals, amino acids, and herbs
or botanicals, as well as other substances," such as a concentrate, metabolite,
constituent, or extract, "that can be used to supplement the diet.").

105.

Id.

106.
Young, 14 Trace Minerals, supra note 53, at 876.
107.
Dietary Supplements, FOOD & DRUG ADMIN., https://www.fda.gov/food/
dietarysupplements/ (last visited Apr. 3, 2019).

2019]

REGULATION OF ENCAPSULATED PLACENTA

245

As a result, the manufacturer is not required to conduct any clinical
trials demonstrating the product's safety or efficacy. Once on the
market, however, FDA has the authority to remove adulterated or
10 8
But supplements
misbranded supplements from commerce.
generally enjoy a presumption of safety. This means that unlike
drugs, whose manufacturers bear the burden of proving to FDA that
their product is safe, FDA cannot pull a supplement from the market
1 09
The
until the agency proves that the supplement is unsafe.
ban
to
agency
the
presumption makes it practically difficult for
supplements, and many have criticized the supplement regulations
10
for failing to adequately protect consumers.
One subset of supplements, however, is not presumed safe:
supplements containing a "new dietary ingredient" ("NDI"). FDA
defines an NDI as "a dietary ingredient that was not marketed in the
United States before October 15, 1994," unless it has "been present in
the food supply as an article used for food in a form in which the food
has not been chemically altered.""' Encapsulated placenta contains
an NDI as human placental tissue is not currently in the food supply
and was not marketed in the United States before 1994. Supplement
manufacturers hoping to sell a product containing an NDI must also
obtain FDA approval before entering the market. At least seventy-five
days before the NDI is sold, the manufacturer must submit
information to FDA demonstrating that the NDI is "reasonably
expected to be safe under the conditions recommended or suggested
in the labeling." 112 "[Inless there is a history of use or other evidence
will
of safety establishing that the new dietary ingredient ...
are
NDIs
containing
supplements
safe,"
be
to
expected
be
reasonably

108.

Id.

Debra D. Burke & Anderson P. Page, Regulating the Dietary Supplements
109.
Industry: Something Still Needs to Change, 1 HASTINGS BUS. L.J. 119, 128 (2005);
Margaret Gilhooley, Deregulation and the Administrative Role: Looking at Dietary
Supplements, 62 MONT. L. REV. 85, 119 (2001) [hereinafter Gilhooley, Deregulation];
Katharine A. Van Tassel, Slaying the Hydra: The History of Quack Medicine, the
Obesity Epidemic and the FDA's Battle to Regulate DietarySupplements Marketed As
Weight Loss Aids, 6 IND. HEALTH L. REV. 203, 216 (2009) ("[T]he FDA carries the
burden of removing an unsafe or ineffective product by proving that it is adulterated
or misbranded.").
See, e.g., Burke & Page, supra note 109, at 129-30; Gilhooley, supra note
110.
109, at 127; Van Tassel, supra note 109, at 251.
21 U.S.C. § 350b(d) (2012); 21 U.S.C. § 350b(a)(1) (2012); FDA, DIETARY
111.
SUPPLEMENTS, supra note 96, at 10, 13.
112. New DietaryIngredients in Dietary Supplements-Backgroundfor Industry,
https://www.fda.gov/Food/DietarySupplements/ucm
ADMIN.,
DRUG
&
FOOD
109764.htm#whatis (last updated Aug. 11, 2016) [hereinafter New Dietary
Ingredients].
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considered "adulterated" and selling them is illegal.1 13 Recently, FDA
announced its intention to revamp its NDI compliance program to
ensure that the agency is reviewing the safety of products containing
NDIS. 114
The NDI approval process is much less rigorous than the
premarket approval process for drugs. First, the supplement
manufacturer need not prove efficacy, only safety. And second, the
manufacturer need not prove safety through double-blind, placebocontrolled studies. Rather, supplement manufacturers can show the
NDI's safety with "safety studies," "adequate history of safe use," and
even "animal testing." 115 Of course, the safety standard is not
perfunctory; FDA only approves roughly 30% of new dietary
ingredient applications (though some of the rejected NDIs contain
very obvious safety issues). 116
In 2002, a company selling encapsulated sheep placenta sought
NDI approval from FDA.117 FDA rejected the application, finding that
the company failed to support its assertion that sheep placenta "has
been in the United States food market for many years" or that it was
safe if used as a supplement.118 FDA noted, however, that the
company's submission failed to meet even the most basic aspects of
the NDI application, such as the requirement to include copies of the
academic articles supporting its position and an explanation of how
they are relevant. 119 It is therefore not predictive of how FDA would
evaluate a serious NDI application for the related, but
113.
New Dietary Ingredients, supranote 112.
114.
Statement From FDA Commissioner Scott Gottlieb, M.D., on the Agency's
New Efforts To Strengthen Regulation of Dietary Supplements by Modernizing and
Reforming FDA's Oversight, FOOD & DRUG ADMIN., https://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm631065.htm (Feb. 11, 2019).
115.
FDA, DIETARY SUPPLEMENTS, supra note 96, at 67; Ashish R. Talati New
Dietary Ingredient Notifications:A Comprehensive Review and Strategiesfor Avoiding
FDA Objections, 62 FOOD & DRUG L.J. 387, 395 (2007) ("[There is no limitation on
what evidence a manufacturer/distributor can use for this safety determination. FDA
will consider animal and human toxicology data and any citation to published articles
or other evidence that is the basis on which the manufacturer or distributor has
concluded that the new dietary supplement will provide this reasonable expectation of
safety.").
116.
Talati, supra note 115, at 390. DMAA was rejected because the ingredient
was found to cause shortness of breath, high blood pressure, and heart attack. DMAA
in Products Marketed as Dietary Supplements, FOOD & DRUG ADMIN. (Aug. 2018),
https://www.fda.gov/Food/DietarySupplements/ProductsIngredients/ucm346576.htm.
117.
FOOD & DRUG ADMIN., FDA-2003-S-0732, NDI 139 - Sheep Placenta from
YAT CHAU
(USA)
INC.
(Nov. 22, 2002),
available at https://www.reg
ulations.gov/document?D=FDA-2003-S-0732-0057
118.
Id.

119.

Id.
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distinguishable, human placenta. Given the influx of research
studying placentophagy in the past five years-including the first
clinical trial-and its lack of adverse events for women consuming
120
manufacturers should be able to make
properly processed placenta,
a good case that encapsulated placenta is "reasonably expected to be
safe" when properly processed and obtain approval as a new dietary
ingredient.
While avoiding onerous market-entry requirements, supplement
manufacturers do not enjoy the same benefits as drug manufacturers.
12
First, they are not entitled to market exclusivity. 1 This is reasonable
because supplement manufacturers do not make the same investment
in research as drug manufacturers. As a result, exclusivity as a
mechanism to recapture lost investment is unnecessary.
Second, it is illegal for supplement manufacturers "to market a
dietary supplement product as a treatment or cure for a specific
22
disease, or to alleviate the symptoms of a disease."1 FDA often issues
warning letters to supplement manufacturers that market their.
123
Warning letters order a
products using disease claims.
manufacturer to stop making a disease claim or else FDA will remove
24
the product from the market as an unapproved drug.1 In 2015, FDA
even issued such a warning letter to a company selling encapsulated
sheep placenta, claiming that it could improve Alzheimer's disease,
cancer, diabetes, heart disease, multiple sclerosis, and Parkinson's

&

See supra Part I; see supra notes 75-77.
120.
Supplements already on the market will fail to meet the novelty requirement
121.
protection. Eisenberg, supra note 97, at 359-60. Though these products
patent
for
could technically obtain FDA exclusivity if they were to be approved as a new drug,
they would be dependent on FDA to enforce the exclusivity, which FDA does not
always do. For instance, FDA approved as a drug a hormone that was already on the
market, yet it declined to enforce the manufacturer's exclusivity due to concerns with
patient access. If FDA were to approve a widely-available supplement as a drug, the
agency would be under similar pressure to not enforce exclusivity. Rachel E. Sachs
Carolyn A. Edelstein, Ensuring the Safe and Effective FDA Regulation of Fecal
Microbiota Transplantation,2 J. L. & BIOSCIENCES 396, 404-05 (2015).
122. FDA 101: Dietary Supplements, FOOD & DRUG ADMIN., https://www.fda.gov/
ForConsumers/ConsumerUpdates/ ucm050803.htm (last updated July 15, 2015).
Of the warning letters FDA has issued in 2017, two have been related to
123.
supplement manufacturers making illegal health claims (Biomin Industries and Total
Body Nutrition). 2017 Warning Letters, Inspections, Compliance, Enforcement, and
Criminal Investigations, FOOD & DRUG ADMIN., https://www.fda.gov/ICECI/
EnforcementActions/WarningLetters/2017/default.htm (last updated Mar. 31, 2019)
[hereinafter 2017 Warning Letters].
ADMIN.,
DRUG
&
FOOD
Letters,
Warning
e.g.,
124. See,
https-//www.fda.gov/food/complianceenforcement/warning letters/default.htm.
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disease.125 The privilege of making disease claims is reserved for the
manufacturers whose products have been proven to be effective at
curing, treating, mitigating, or preventing disease, which is not
generally true for supplements.
In contrast, FDA regulations allow supplement manufacturers to
make structure and function claims about their products: "Dietary
supplement labels . .. may ...

bear statements that describe the role

of a nutrient or dietary ingredient intended to affect the structure or
function in humans ... provided that such statements are not disease
claims . . . ."126 Manufacturers may also make nutrient deficiency
claims.1 27 Before making a structure, function, or nutrient deficiency
claim, FDA requires that manufacturers: (1) "have substantiation
that the claims are truthful and not misleading," (2) notify FDA of the
claim within thirty days, and (3) "include a mandatory disclaimer."1 2 8
The disclaimer must state: "This statement has not been evaluated by
the Food and Drug Administration. This product is not intended to
diagnose, treat, cure, or prevent any disease."1 29 FDA imposes a less
rigorous standard on structure, function, and nutrient deficiency
claims because those claims are less likely to be "beyond the ability of
the consumer to evaluate."1 3 0 As one might imagine, however, the line
between a disease claim and a structure or function claim is not
always clear, and courts may be unwilling to enforce FDA
determinations that a manufacturer cannot make a particular health
claim.131
Supplement manufacturers must also abide by good
manufacturing practice rules, which set standards for the quality of
the ingredients, the cleanliness of the facility, and the maintenance of

125.
FOOD & DRUG ADMIN., ADVISORY LETTER-LIFE DECODERS, LLC 1 (2016),
https://www.fda.gov/ICECI/EnforcementActions/AdvisoryLetters/ucm478529.htm
[hereinafter FDA, ADVISORY LETTER-LIFE DECODERS, LLC].
126.
21 C.F.R. § 101.93(f) (2008).
127.
Id. § 101.93(g).
128.
Guidance for Industry: Structure/Function Claims; Small Entity
Compliance Guide, FOOD & DRUG ADMIN., https://www.fda.govFood/Guidance
Regulation/GuidanceDocumentsRegulatoryInformation/DietarySupplements/ucmlO3
340.htm (last updated Nov. 10, 2017) [hereinafter Guidance for Industry:
Structure/FunctionClaims].
129.
21 C.F.R. § 101.93(c) (2008).
130.
Margaret Gilhooley, Herbal Remedies and Dietary Supplements: The
Boundaries of Drug Claims and Freedom of Choice, 49 FIA. L. REV. 663, 688 (1997)

[hereinafter Gilhooley, Herbal Remedies]; see also infra, Section IV.B.1.
131.
Gilhooley, Deregulation, supra note 109, at 115-16; see also Pearson v.
Shalala, 164 F.3d 650, 655-56 (1999). FDA, however, has provided regulations for how
to identify disease claims at 21 C.F.R. § 101.93(g)(2).
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records and customer complaints. 13 2 As part of these rules,
manufacturers are legally required to "report to FDA any serious
adverse events that are reported to them by consumers or health care
professionals." 133 FDA also polices manufacturers' compliance with
these regulations and issues warning letters when its inspections
34
reveal violations.1
3. Human Tissues: A Bifurcated Approach
A third possible regulatory characterization of encapsulated
placenta could be as a human cell, tissue, and cellular- or tissue-based
product ("HCT/Ps"). FDA defines HCT/Ps as "articles containing or
consisting of human cells or tissues that are intended for
implantation, transplantation, infusion, or transfer into a human
recipient."1 35 Encapsulated placenta meets this definition because it
1 36
into the
consists of a human tissue that is intended for transfer
person who consumes it.137

The HCT/P regulations represent a "tiered, risk-based approach,"
which attempt to isolate the HCT/P products that are least likely to
1 38
HCT/Ps are
cause safety issues and regulate them less stringently.
of drugs
a
subset
regulated in one of two ways: either (A) as a biologic,

See generally Current Good Manufacturing Practice in Manufacturing,
132.
Packaging, Labeling, or Holding Operations for Dietary Supplements, 72 Fed. Reg.
111),
§
C.F.R.
21
at
codified
be
(to
2007)
25,
(June
34751
39
.htm.
https://www.gpo.gov/fdsys/pkg/FR-2007-06-25/html/07-30
133. FDA 101: Dietary Supplements, supra note 122.
134. In 2017, three supplement manufacturers (Create-a-Pack Foods, Nexagen,
and Total Body Nutrition) received a warning letter for violations of the good
manufacturing practice rules. 2017 Warning Letters, supra note 123.
21 C.F.R. § 1271.3(d) (2008). The definition also excludes eight categories of
135.
products from this definition, none of which are relevant to this Article. Id.
136. "Transfer means the placement of human reproductive cells or tissues into a
human recipient." Id. § 1271.3(g).
137. Encapsulated placenta could possibly escape HCT/P regulation entirely
through an exception for articles "secreted or extracted from human products, such as
milk, collagen, and cell factors." Id. § 1271.3(d)(3) (2008). Though the placenta is
secreted through the normal birth process, it is unclear whether FDA would find that
the product meets this exception. For instance, the agency regulates products made
from the amniotic membrane and umbilical cord as HCT/Ps even though they too were
secreted during birth. FOOD & DRUG ADMIN., REGULATORY CONSIDERATIONS FOR
HUMAN CELL, TISSUES, AND CELLULAR AND TISSUE-BASED PRODUCTS: MINIMAL
MANIPULATION AND HOMOLOGOUS USE 10, 15 (2017), https://www.fda.gov/
downloads/BiologicsBloodVaccines/GuidanceComplanceRegulatorylnformation/Guid
[hereinafter FDA, REGULATORY
ances/CellularandGeneTherapyUCM585403.pdf
CONSIDERATIONS FOR HCT/PS]
FDA, REGULATORY CONSIDERATIONS FOR HCT/PS, supra note 137, at 2.
138.
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made from human, animal, or microorganism sources that are also
required to undergo premarket review, 139 or (B) under lessburdensome regulations found in Section 361 of the Public Health
Service Act. 140 If the latter, they are designated "361 HCT/Ps." HCT/P
manufacturers141 qualify for these less onerous regulations if they
satisfy the four elements of 21 C.F.R. § 1271.10(a). These elements
require that (1) "[tjhe HCT/P is minimally manipulated";142 (2) "[t]he
HCT/P is intended for homologous use only,"l 43 which means that the
human tissue must "perform[] the same basic function or functions in
the recipient as in the donor"; 1 " (3) "[tlhe manufacture of the HCT/P
does not involve the combination of the cells or tissues with another
article";1 45 and (4) either:
(i) The HCT/P does not have a systemic effect and is not
dependent upon the metabolic activity of living cells for its
primary function; or
(ii) The HCT/P has a systemic effect or is dependent upon the
metabolic activity of living cells for its primary function, and:
(a) Is for autologous use;
(b) Is for allogeneic use in a first-degree or second-degree
blood relative; or
(c) Is for reproductive use. 146
If a product qualifies as a 361 HCT/P by satisfying all four
elements, it is not required to undergo premarket review. 147 Instead,

139.
BiologicalProductDefinitions: What Is a Biological Product?, FOOD & DRUG
ADMIN. 1, https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/How
DrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplicati
ons/Biosimilars/UCM581282.pdf (last visited Mar. 25, 2019).
140.
21 C.F.R. §§ 1271.10(a), 1271.20 (2008).
141.
FDA defines a HCT/P manufacturer as one who "recover[s], process[es],
stor[es], label[s], packag[es], or distribut[es] ... any human cell or tissue." 21 C.F.R.
§ 1271.3(e) (2008). Placenta encapsulators, at a minimum, recover, process, and store
human tissue and would therefore be regulated as HCT/P manufacturers. See
definitions of process, store, and recover at 21 C.F.R. § 1271(ff), (ii), and (j).
142.
21 C.F.R. § 1271.10(a)(1) (2008).
143.
Id. § 1271.10(a)(2).
144.
Id. § 1271.3(c).
145.
Id. § 1271.10(a)(3). This excludes "water, crystalloids, or a sterilizing,
preserving, or storage agent." Id.
146.
Id. § 1271.10(a)(4).
147.
FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: REGULATION OF HUMAN
CELLS, TISSUES, AND CELLULAR AND TISSUE-BASED PRODUCTS (HCT/PS), SMALL
ENTITY
COMPLIANCE
GUIDE
3
(2007),
https://www.fda.gov/downloads/
BiologicsBloodVaccines/GuidanceComplianceRegulatorylnformation/Guidances/Tissu
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FDA dictates that 361 HCT/P manufacturers must simply: (1) register
with FDA and list the HCT/Ps they manufacture;148 (2) abide by good
manufacturing guidelines that establish minimum sanitary, safety,
149
and competence procedures for sites that handle human tissues;
(3) report adverse events; and (4) allow FDA to inspect facilities for
compliance. 5 0 If the placenta were to be consumed by anyone other
than the woman from whom it came, the manufacturer would also be
5
required to abide by strict donor eligibility requirements.1 1 The 361
HCT/P regulations prevent manufacturers from mixing tissues,
failing to sanitize the tools and spaces used to process tissues, and
creating an environment where human tissues can be crosscontaminated. However, if the four requirements of 21 C.F.R. §
1271.10(a) are not met, then the HCT/P is regulated as a biologic
requiring premarket review as described in Section IIA.152
Encapsulated placenta easily satisfies elements three and four of
21 C.F.R. § 127 1.10(a). Placentophagy providers do not mix the tissue
with another article (satisfying element three) and, even though
placenta pills have a systemic effect, they are used autologously,
meaning that the donor is also the recipient (satisfying element
four).1 53 Encapsulated placenta manufacturers,

however, will be

unable to establish compliance with elements one and two. The first
54
element requires the product to only be minimally manipulated,1
which is defined as "processing 5 5 that does not alter the original
relevant characteristics of the tissue relating to the tissue's utility for
6
reconstruction, repair, or replacement." 5 The relevant biological

e/ucm062592.pdf [hereinafter FDA, REGULATION OF HUMAN CELLS, TISSUES, AND
CELLULAR AND TISSUE-BASED PRODUCTS (HCT/PS)].

148.
149.
150.
151.
152.
153.
154.
155.

21 C.F.R. §§ 1271.21-.37 (2008).
Id. § 1271.145-.320.
Id. § 1271.330-.440.
Id. § 1271.45-.90.
Id. § 1271.20.
Id. § 1271.3(a).
Id. § 1271.10(a)(1).
"Processing . . . includes cutting, grinding, shaping, culturing, enzymatic

digestion, and decellularization." FDA, REGULATORY CONSIDERATIONS FOR HCT/PS,

supra note 137, at 7.
156. 21 C.F.R. § 1271.3(f)(1) (2008). This is the definition of minimal
manipulation for "structural tissues." Id. For "cells and nonstructural tissues,"
minimal manipulation is defined as "processing that does not alter the relevant
biological characteristics of cells or tissues." Id. § 1271.3(f)(2). FDA has issued
guidance on how to distinguish between structural and nonstructural tissues. "Tissues
that physically support or serve as a barrier or conduit, or connect, cover, or cushion
in the donor are generally considered structural tissues for the purposes of
REGULATORY
FDA,
regulatory definition."
applicable
the
determining
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characteristics for structural tissues "generally include the properties
of [the cells or nonstructural tissues] in the donor that contribute to
the cells or tissue's function or functions."157 Because the placenta,
once encapsulated and consumed by mouth, is not intended to have
the same function as it did as an organ inside pregnant women, the
placenta is more than minimally manipulated. For instance, FDA has
stated that if a manufacturer grinds "amniotic membrane and
packages it as particles" then the "HCT/P generally is considered more
than minimally manipulated because the processing alters the
membrane's physical integrity, tensile strength, and elasticity that
allow it to serve as a membranous barrier."1 5 8
The second element of § 1 2 71.10(a)--requiring that the tissue be
intended for homologous use-would also be difficult to demonstrate
for encapsulated placenta. 5 9 "Homologous use means the repair,
reconstruction, replacement, or supplementation of a recipient's cells
or tissues with an HCT/P that performs the same basic function or
functions in the recipient as in the donor."16 0 FDA is concerned about
non-homologous use "because there is less basis on which to predict
the product's behavior, whereas HCT/Ps for homologous use can
reasonably be expected to function appropriately."'16 FDA has also
made clear that this requirement is necessary even when the donor is
the same as the recipient.1 62 Homologous use is established, for
instance, when a heart valve is used to replace a dysfunctional heart
valve or skin replaces damaged skin.1 63 Homologous use therefore
requires a very similar showing as minimal manipulation-that the
tissue functions the same way inside the recipient as it did inside the
donor. Though distinct categories, these elements bleed into one
another.
CONSIDERATIONS FOR HCT/Ps, supra note 137, at 7. FDA's examples of structural

tissue include bone, skin, and amniotic membranes. Id. at 8. By contrast, "[c]ells or
nonstructural tissues are generally those that serve predominantly metabolic or other
biochemical roles in the body such as hematopoietic, immune, and endocrine
functions." Id. at 13. Examples of nonstructural tissue include reproductive cells or
tissues, cord blood, amniotic fluid, and lymph nodes. Id. at 13-14. Although an
argument could be made that placenta falls within either category, it most clearly fits
as a structural tissue because like the amniotic membrane-the innermost part of the
placenta-the placenta acts as a barrier or conduit between the mother and fetus.
157. FDA, REGULATORY CONSIDERATIONS FOR HCT/Ps, supra note 137, at 6.
158.
159.
160.
161.
162.

Id. at 10.
21 C.F.R. § 1271.10(a)(2) (2008).
Id. § 1271.3(c) (2008).
FDA, REGULATORY CONSIDERATIONS FOR HCT/Ps, supra note 137, at 4.
Id. at 15 (clarifying that the regulation includes "when such cells or tissues

are for autologous use").
163.

Id.
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In short, the transformation of an organ that once served as a
conduit between mother and fetus into an oral, powder-based pill
would fail to meet both the minimal manipulation and homologous
use elements. As a result, if encapsulated placenta were regulated as
a human tissue, it would be required to obtain premarket approval as
a biologic.

To summarize, encapsulated placenta arguably meets the
definition of a drug, supplement, and human tissue. Its categorization
will have enormous effects on how the product is regulated. If FDA
decides to treat it as a drug, it would be subject to premarket review
and the manufacturers will have to spend tens of millions of dollars
over many years collecting the research required to prove that the
product is safe and effective before it can be sold. The product will
never enter the market if researchers cannot prove its efficacy.
Supplements, on the other hand, can generally enter the market
directly without FDA approval and remain there unless FDA proves
that it is unsafe or that the manufacturer is making disease claims.
But because encapsulated placenta contains a new dietary ingredient,
manufacturers would be required to demonstrate safety before selling
it as a supplement, albeit through a much less rigorous system than
that required for drugs. Supplements are not required to be effective
at anything to be sold, but manufacturers are limited in the claims
they can make. Finally, if encapsulated placenta is a human tissue, it
could be regulated as a biologic requiring premarket review or enter
the market directly as a 361 HCT/P, required only to abide by
regulations aimed at stopping the spread of communicable diseases.
Encapsulated placenta, however, would likely fail to meet the 361
HCT/P elements, and therefore be regulated as a biologic.
B. Intended Use: FDA's Method for CategorizingMixed Products
Encapsulated placenta is certainly not the only product that meets
multiple FDA categories, but FDA has never before categorized-or
provided guidance on how to categorize-a human tissue that meets
multiple categories. FDA's general approach to categorizing mixed
products 164 is to regulate the product based on its intended use
("Intended Use"). Intended Use refers to "the objective intent of the

164. This is a term I created to describe products that meet multiple categories.
To my knowledge, FDA does not utilize a term to describe these products.
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persons legally responsible for the labeling of [products]. The intent is
determined by such persons' expressions or may be shown by the
circumstances surrounding the distribution of the article."16 5 In other
words, when a product could meet multiple definitions, FDA
determines under which category the manufacturer intends the
product to fall and regulates it accordingly. Intended Use is generally
established by reference to "labeling claims, advertising matter, or
oral
or
written
statements by
such persons
or
their
representatives." 166
Intended Use is most frequently invoked when FDA is confronted
with products that could be either supplements or drugs-i.e.,
products that contain a dietary ingredient but could be used to treat
disease. If the manufacturer markets the product as capable of
diagnosing, treating, curing, or preventing disease, then the
manufacturer intends the product to be a drug and it will be regulated
as a drug. 16 7 However, if the product meets the definition of a
supplement and the manufacturer markets it as a supplementwithout making disease claims-then FDA will regulate it as a
supplement.1 6 8 Unfortunately, many products enter the market as
supplements and illegally make disease claims; in those instances,
FDA will issue a warning letter to the manufacturer describing the
improper statements and directing it to either remove the claims or
seek premarket approval to market the product as a drug. 16 9 FDA can
remove a product from the market if it does not comply. Given the
enormous burden of drug regulation, manufacturers almost always
alter their marketing to remove any disease claims and continue to be
regulated as a supplement. As a result, any rational encapsulated
placenta manufacturer would avoid making disease claims to prevent
drug regulation under the Intended Use paradigm.170
But assuming that encapsulated placenta manufacturers cease all
disease claims, the agency would still have a choice to make: regulate
encapsulated placenta purely as a supplement, probably requiring

165.
21 C.F.R. § 801.4 (2008).
166.
Id.
167.
Guidancefor Industry: Structure/FunctionClaims, supra note 128.
168.
Id. In certain circumstances, however, FDA will exercise enforcement
discretion to allow supplement manufacturers to make disease claims that have been
sufficiently proven. See, e.g., Qualified Health Claims, FOOD & DRUG ADMIN.,
https://www.fda.gov/Food/LabelingNutrition/ucm2006877.htm (last updated Feb. 2,
2019).
169.
See 2017 Warning Letters, supra note 123.
170.
FDA even issued such a warning letter to a manufacturer selling sheep
placenta with disease claims. FDA, ADVISORY LETTER-LIFE DECODERS, LLC, supra
note 125, at 1.
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new dietary ingredient approval, or regulate it as a human tissue.
Theoretically, Intended Use should involve the same calculus for
human-tissue supplements as it does for drug supplements. After all,
17
human tissues are a subset of biologics, which are a subset of drugs. 1
But unlike drugs, which are defined by their intent for use-to treat
diseasel 72-human tissues are defined by their intended destination"human cells or tissues that are intended for implantation,
73
transplantation, infusion, or transfer into a human recipient."1
Thus, avoiding human tissue regulation may not be as easy as
avoiding drug regulation. If the product is a human tissue intended
for transfer into a recipient, there is no easy marketing fix to stave off
the human tissue regulations, even assuming the tissue is solely
intended to supplement the diet.
FDA has never directly answered how it would regulate products
that are both human tissues and supplements. Probiotics present the
most similar case study. As live micro-organisms, probiotics are both
74
biologics and supplements.1 FDA's current approach has been to
regulate probiotics on a case-by-case basis, sometimes as
75
supplements, sometimes as food, sometimes as drugs.1 FDA seems
primarily concerned about whether probiotics found within
supplements or conventional foods are marketed with drug claims, not
whether the live microorganisms are properly handled under the
biologic regulations.176 And thus far, meeting the definition of a
biologic has not usurped a probiotic's ability to be regulated as a
supplement. The University of Maryland recently published a ninety-

&

Frequently Asked Questions About TherapeuticBiological Products,FOOD
171.
DRUG ADMIN., https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsarE
13
developedandapproved/approvalapplications/therapeuticbiologicapplications/ucm
522.htm (last updated July 7, 2015).
FDA defines a drug as "contain[ing] a drug substance," which is an
172.
ingredient intended for use "in the diagnosis, cure, mitigation, treatment, or
prevention of disease or to affect the structure or any function of the human body." 21
C.F.R. § 314.3(b) (2008).
21 C.F.R. § 1271.3(d) (2008). The definition also excludes eight categories of
173.
products from this definition, none of which are relevant to this Article. Id.
174. DIANE E. HOFFMANN ET AL., FINAL REPORT: FEDERAL REGULATION OF
PROBIOTICS: AN ANALYSIS OF THE EXISTING REGULATORY FRAMEWORK AND
(2016),
19-20
FRAMEWORKS
ALTERNATIVE
FOR
RECOMMENDATIONS
https://www.law.umaryland.edulmedia/SOL/pdfs/Programs/H-ealth-Law/FinalW-hiteP
aper.pdf ("FDA considers probiotics to be biological products").
175. Id. at 19.
See, e.g., Warning Letter for Bio TE Medical, FOOD & DRUG ADMIN. (May 22,
176.
2
https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ 017/ucm
2017),
561444.htm.
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page report with recommendations on how to regulate probiotics, 177
but FDA has yet to establish a long-term position. 178
If FDA decided to regulate encapsulated placenta as a human
tissue because it is intended for transfer into a human recipient, then
encapsulated placenta manufacturers would be forced to obtain
premarket review. As a reminder, the HCT/P regulations are
bifurcated. Products either meet the elements of a 361 HCT/P, which
are regulated lightly, or must obtain premarket approval as a biologic.
As noted in Section II.A.3, encapsulated placenta fails to meet two of
the four criteria for 361 HCT/P regulation: minimal manipulation and
homologous use.1 79 It would therefore be regulated under FDA's
strictest standard. Alternatively, if FDA chooses to ignore the human
tissue regulations-as it has (at least temporarily) ignored the
biologic regulations for probiotics-then encapsulated placenta would
be regulated as either a drug or supplement depending on whether it
made disease claims. Practically speaking, under this scenario,
encapsulated placenta manufacturers would drop disease claims and
be regulated as supplements.
FDA's regulatory scheme does not provide clear answers on how
encapsulated placenta should be regulated. In light of this
uncertainty, a policy analysis would be particularly useful at
illuminating the ideal categorization available to the agency. Part III
explores two policy considerations that the agency should consider in
regulating encapsulated placenta: the need to balance consumer
safety against consumer access and the gender-based implications
surrounding the state's regulation of products associated with fertility
and childbirth. These considerations suggest that though some
regulation of encapsulated placenta is needed to establish a safety
floor, it should not be so stringent that women lose access to the
product.

177.
See generally HOFFMANN ET AL., supra note 174.
178.
There is reason to think FDA might not be so lenient for encapsulated
placenta. Probiotics have been consumed safely in conventional foods like yogurt for
many years, which might cause the agency to feel more comfortable leaving them less
regulated.
179.
See supra Section IIA.3.
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III. PUBLIC POLICY CONCERNS IN REGULATING PLACENTOPHAGY
In evaluating whether and how to regulate a product, FDA must
balance competing goals. Its primary purpose is to protect the public
from the risks of unsafe or ineffective products.1so But FDA is also
mandated to help ensure that health-related innovations are
accessible to the public.18 1 These two values are often in tension as
FDA balances the public's interest in having immediate access to a
new treatment against its need to be protected from unknown
harms.1 82 For any given product, the balance of these two interests
yields different results on how much regulation is required.
Fundamentally, FDA's category-based regulatory system reflects
the notion that different kinds of products, with their varying levels
of risk, should be regulated differently. Drugs are regulated the most
extensively because they pose the greatest risk of harm, while
conventional foods are regulated very lightly because it is generally
considered

safe. 183

Concerns

over

consumer

access

are

also

encompassed in each category's regulatory structure. Because the
patent system financially incentivizes the creation of novel drugs,
burdensome regulations for drugs are less likely to diminish a
consumer's long-term access to medications, whereas products for

which market exclusivity is unavailable-like

supplements and

conventional foods-must be regulated less harshly to ensure that the
product does not disappear from the market entirely. 184 Thus, at least

at a high level, the regulations governing each of FDA's categories can
be construed as striking a particular balance between consumer
access and consumer safety as related to that class of products. These
concepts are explored in greater detail throughout this Article.
Mixed products are more complicated, however, because they do
not easily fit into any of FDA's predetermined categories. FDA is
therefore faced with a dilemma: Should it regulate the product
according to the more rigorous or more lenient system? Should it
regulate the product according to one category or multiple categories?
Or if the product is unique, should it craft freestanding regulations to
govern it or leave it completely unregulated? It is exactly in these
ambiguous circumstances that the policy concerns underlying FDA
regulation can best guide agency decision-making.

What We Do, supra note 85.
180.
Id. ("FDA is responsible for advancing the public health by helping to speed
181.
innovations that make medical products more effective, safer, and more affordable.").
See infra Part III.
182.
See infra Part III; see also HOFFMANN ET AL., supranote 174, at 21.
183.
See infra Section II.A.
184.
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This Part starts with an examination of the policy values that
must be balanced for all FDA regulation: consumer access and
consumer safety. I look to how these goals are balanced for
supplements and drugs as a way to explain placentophagy advocates'
countervailing concern about the regulation of encapsulated placenta.
It then explores of the centrality of gender to any debate of whether
to regulate a product associated with childbirth and fertility,
especially in light of the criticism that the state tends to overregulate
women's bodies immediately before, during, and after pregnancy.
Both of these discussions reveal the need to regulate the product on
some level, but not so much as to render it unavailable.
A. Balancing Consumer Safety Against Consumer Access
The tension between consumer access and safety is ever present
in the debate over FDA regulation, whether the dispute is about a
specific product or a class of products.1 85 Regarding safety, FDA
regulation protects consumers against misinformation and
adulteration by ensuring that manufacturers are not fabricating
miracle cures, releasing dangerous and untested products onto the
market, or lying about their products' benefits.18 6 Just this year, the
World Health Organization found that over 10% of the drugs sold in
the developing world-where the pharmaceutical industry is less
regulated-are substandard or falsified, which has led not only to
consumers unknowingly spending their money on knock-offs, but the
progression of serious illness and death to patients consuming
them. 187 FDA's regulatory protection, however, comes with a negative

185. Lewis A. Grossman, AIDS Activists, FDA Regulation, and the Amendment of
America's Drug Constitution, 42 AM. J.L. & MED. 687, 691 (2016) (describing the
"sometimes contrary" fundamental purposes of FDA: (1) "guarding the public health
by protecting consumer from hazardous and ineffective products" and (2) "promoting
the expeditious release of potential effective treatments, both to advance public health
and to enhance consumer choice"); Eisenberg, supra note 97, at 346 ("Throughout this
period the most politically compelling arguments in favor of regulation emphasized
public health and the protection of patients from unknown hazards, while the most
compelling arguments against regulation emphasized the interests of patients and
doctors in making their own therapeutic choices unfettered by government
regulation."); Michael D. Greenberg. AIDS, ExperimentalDrug Approval, and the FDA
New Drug Screening Process, 3 LEGIS. & PUB. POL'Y 295, 296 (2000) (describing the
costs and benefits of FDA regulation).
186. See generally Developments in the Law-the Federal Food, Drug, and
Cosmetic Act, 67 HARV. L. REV. 632 (1954).
187. 1 in 10 medical products in developing countries is substandardor falsified,
WORLD HEALTH ORG. (Nov. 28, 2017), http://www.who.int/mediacentre/news/
releases/2017/substandard-falsified-products/en/.
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side effect: reduced access to helpful medications. FDA regulation can
prevent products from entering the market, discourage innovation,
raise prices, and waste resources.188 Reduced access also harms
consumers, who miss the benefits of new products, some of which
might also be lifesaving while the agency determines if the product is
safe and effective.18 9
The debate over whether, and how, to regulate encapsulated
placenta involves the same tension. Encapsulated placenta providers
argue that they cannot afford to abide by burdensome regulations, and
thus, if FDA regulates them too harshly, the product will disappear
from the market. Others argue, however, that the product is unproven
and potentially dangerous. If the government does not regulate it,
they say, consumers will be exposed to safety risks and there will be
no incentive for anyone to generate data on whether the product
actually works.
These same concerns were raised during the national conversation
over how to regulate dietary supplements. 1so Before the Dietary
Supplement Health and Education Act ("DSHEA") was passed in
1994, FDA threatened to start enforcing its drug regulations against
supplement manufacturers,1 91 which would have required
19 2 Congress passed the
supplements to obtain premarket approval.
DSHEA in response to public outrage that individuals might lose
access to supplements if manufacturers were forced to adhere to the
19 3
The DSHEA defined
harsh premarket approval requirements.
Grossman, supra note 185, at 691 ("As a formal matter, the Act curbs the
188.
conduct of manufacturers and distributors, not their customers. Nevertheless, when
the FDA prevents the sale of a product altogether, the Agency also indirectly limits
the rights of consumers who want that product."); Eisenberg, supra note 97, at 367
("[T]he FDA is often criticized as a paternalistic bureaucracy interposing costly
barriers between patients who demand new products and firms that are eager to

supply them.").
For instance, patient advocates sued FDA arguing that terminally-ill
189.
patients have a constitutional right to access investigational drugs. Dresser, supra
note 95, at 1635-38.
Gilhooley, Deregulation, supra note 109, at 91-93.
190.
FDA threatened to start regulating supplements as drugs after thirty-eight
191.
people died from consuming an amino acid supplement. Id. at 92. Before this, FDA
was regulating supplements as food additives. Jennifer Akre Hill, CreatingBalance:
Problems Within DSHEA and Suggestions for Reform, 2 J. FOOD L. & POL'Y 361, 366
(2006). For a comprehensive discussion of the long history of supplement regulation,
see Gilhooley, Herbal Remedies, supra note 130, at 671-79.
Hill, supra note 191, at 367; see also infra Part IV.
192.
Ryan Abbott, Treating the Health Care Crisis: Complementary and
193.
Alternative Medicine for PPACA, 14 DEPAUL J. HEALTH CARE L. 35, 68-73 (2011) ("In
1994, after an attempt by the FDA to restrict commercial availability of dietary
supplements, approximately two million letters were sent to members of Congress to
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supplements as foods, permitting them to enter the market without
FDA approval; but it limited supplement manufacturers' ability to
make certain health claims about their products, explored in greater
detail below. 194 For instance, supplements cannot be marketed as
being able to cure, mitigate, prevent, or treat any disease.1 95 Had
Congress not enacted the DSHEA, the public's access to supplements
would be greatly reduced today.19 6
Rebecca S. Eisenberg uses market exclusivity to explain why
regulating supplements as drugs would have substantially reduced
the public's access to supplements. 197 Premarket approval requires
manufacturers to fund expensive research proving that their product
is both safe and effective.198 Unlike supplements, drugs generally
enjoy a period of patent exclusivity when they first enter the
market. 199 This market exclusivity allows pharmaceutical companies
to recoup the money spent on research and utilize the research's
findings to market their product without competitors piggybacking off
of their work. 200 Without exclusivity, however, "competitors can share
in the benefits of [the research a manufacturer funds] without sharing
in the costs of producing it."201 In this situation, there is no incentive
to produce the research because the costs cannot be recouped.
Supplement manufacturers are generally excluded from the
patent system because patents are only available for discoveries or

fight for consumer access. In justifying the resulting Dietary Supplement and Health
Education Act, Congress cited 'overwhelming public pressure' favoring improved
access."); Hill, supra note 191, at 370-71; Burke & Page, supra note 109, at 128. This
public concern was due to, at least in part, a supplement industry campaign to
persuade the public that the DSHEA would be bad for consumers. Gilhooley,
Deregulation,supra note 109, at 93.
194.
Gilhooley, Herbal Remedies, supra note 130, at 684-86.
195.
FDA 101: Dietary Supplements, supra note 122.
196.
Eisenberg, supra note 97, at 379-80; Gilhooley, Deregulation, supra note
109, at 92-93.
197.
Eisenberg, supra note 97, at 379-80; see also Gilhooley, Herbal Remedies,
supra note 130, at 711.
198.
Hill, supra note 191, at 367.
199.
Eisenberg, supra note 97, at 379-80.
200. Id. at 355.
201.
Id. at 379; see also id. ("Suppose the manufacturer of an unpatented vitamin
or dietary supplement believes that it could increase demand for its product by
conducting clinical trials to convince skeptics that it is safe and effective. At best, the
seller would have to share the expanded market with competitors who did not share
in the cost of information provision."); Gilhooley, Herbal Remedies, supra note 129, at
711 ("The 'gold standard' of controlled scientific testing can be seen as too demanding
for natural products when they cannot obtain protection for research that the patent
system makes possible for drugs synthesized and developed by pharmaceutical
companies.").

2019]

REGULATION OF ENCAPSULATED PLACENTA

261

creations of novel compounds, and supplements are generally made
202
And
from naturally occurring ingredients already on the market.
though regulatory exclusivity is theoretically available to them, FDA
has an uneven history in enforcing the exclusivity when a product had
203
The fact that
previously been sold by multiple providers.
of clinical
value
the
"capture
cannot
supplement manufacturers
dietary
"[i]f
that
indicates
trials" through market exclusivity
as
standards
regulatory
supplements were subjected to the same
improved
be
not
patented drugs, the most likely result would
information provision, but the disappearance of these products from
the market." 204
Proponents of the DSHEA argued that limiting access to
anomalous given that
supplements would be particularly
than drugs. 205 There
dangerous
less
much
supplements are generally
is truth to this; for instance, consumers self-reported 649 deaths
caused by pharmaceuticals in 2015.206 By contrast, consumers only
Abbott, supra note 193, at 68-73; Joshua H. Biesler, Dietary Supplements
202.
and Their Discontents: FDA Regulation and the Dietary Supplement Health and
Education Act of 1994, 31 RUTGERS L.J. 511, 516 n.22 (2000) ("[U]nlike new
pharmaceuticals, dietary supplements cannot be patented, and this fact makes the
return on this massive investment far from assured in the context of the dietary
supplement industry."); Judd Cooper Legum, The Dangers of DSHEA- A Case for
Expanded FDA Authority over Dietary Supplements, 6 J. MED. & L. 103, 119 (2002).
Rachel E. Sachs & Carolyn A. Edelstein, Ensuring the Safe and Effective
203.
FDA Regulation ofFecal Microbiota Transplantation,2 J. L. & BIOSCIENCES 396, 40405 (2015); see supra note 121.
Eisenberg, supra note 97, at 379-80; see also Legum, supra note 202, at 119
204.
("The rationale behind DSHEA is that if dietary supplements were subject to the same
safety standards as drugs, then they would not be available.").
Beisler, supra note 202, at 524 (noting "the extremely low number of injuries
205.
reported that were attributed to the use of dietary supplements," especially "[w]hen
compared to the injuries and fatalities that result from the use of FDA-approved
drugs").
James B. Mowry et al., 2015 Annual Report of the American Association of
206.
Poison Control Centers'NationalPoisonDataSystem (NPDS): 33rd Annual Report, 54
https://aapcc.s3.amazonaws.com/
(2016),
1086
924,
CLINICAL TOXICOLOGY
These
pdfs/annual-reports/2015_AAPCCNPDSAnnualReport_33rdPDF.pdf.
numbers are typically viewed as under representations; in hospital patients alone, it
is estimated that adverse drug reactions cause 106,000 to 128,000 deaths annually,
even despite how closely they are regulated. Donald W. Light, New PrescriptionDrugs:
A Major Health Risk With Few Offsetting Advantages, HARV. UNIV. (June 27, 2014),

-

https://ethics.harvard.edulblog/new-prescription-drugs-major-health-risk-fewoffsetting-advantages; Michael 0. Schroeder, Death By Prescription, U.S. NEWS
2 16
(Sept. 27, 2017), https/health.usnews.com/health-news/Patient-advice/articles/ 0
Drug
Preventable Adverse
09-27/the-danger-in-taking-prescribed-medications;
ADMIN.,
Focus on Drug Interactions, FOOD & DRUG
Reactions: A
www.fda.gov/Drugs/DevelopmentApprovalProcess/Development
Resources/DrugInteractionsLabelng/ucml 10632.htm (last visited Mar. 25, 2019).
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reported three deaths caused by vitamins and supplements in the
same year. 207 This large difference is startling when one considers
that FDA extensively regulates pharmaceuticals before they enter the
market-and yet the death rate is still comparatively high-and FDA
only minimally regulates supplements, and the supplement death
rate is nevertheless very low. This is not to say that supplements are
categorically safe. Individual supplements can be dangerous, 208 and
even safe supplements can expose consumers to health risks at certain
doses or in particular circumstances.209 But supplements raise
significantly
fewer
safety
concerns
than pharmaceuticals.
Supplements, almost by definition, are products that have been either
on the market for decades or are regularly consumed by the public
through a normal diet. 210
For Congress, the need to protect the public's access to
supplements outweighed the risk to public safety that supplements
posed: the "DSHEA ... is firmly grounded in Congress' recognition
that consumers want information about and access to a broad range
of safe products." 2 11 Congress' determination that supplements did
not pose a great enough safety risk to so starkly limit consumer choice
was reflected in much of the legislative history associated with the
Act.2 12 Proponents believed in a freedom-of-choice theory, which

207.
Mowry et al., supra note 206, at 1068, 1080-81.
208.
For instance, supplements containing ephedrine caused 800 adverse events.
Gilhooley, Deregulation,supra note 109, at 120. FDA also banned L-tryptophan after
one manufacturer's product contained a contaminant that caused eosinophiliamyalgia syndrome in 1,500 individuals. Beisler, supra note 202, at 528.
209.
For instance, supplements can cause adverse health risks when consumed
with prescription drugs. See Stephanie Kauflin, Dietary Supplements: Is Availability
Worth the Risks? ProposedAlternatives to the PresentDSHEA Scheme, 33 SETON HALL
L. REV. 411, 411 (2003); Gilhooley, Deregulation, supra note 109, at 118. And
furthermore, consumers may undercount supplement risks because of a psychological
phenomenon whereby individuals assume that familiar and natural products are safe.
Dana Ziker, What Lies Beneath: An Examination of the Underpinnings of Dietary
Supplement Safety Regulation, 31 AM. J.L. & MED. 269, 276 (2005).
210.
If a supplement contains a dietary ingredient that has not "been present in
the food supply as an article used for food in a form in which the food has not been
chemically altered," then it is a "new dietary ingredient" and must undergo its own
form ofpremarket review. 21 U.S.C. § 350b(a)(1) (2008); FDA, DIETARY SUPPLEMENTS,
supra note 96, at 10.
211.
Scott Bass & Emily Marden, The New DietaryIngredient Safety Provisionof
DSHEA: A Return to CongressionalIntent, 31 AM. J.L. & MED. 285, 287 (2005).
212.
Senator Orrin Hatch, for instance, stated that "most of these [products] have
been on the market for 4,000 years, and ... there is not much risk." Legis. Issues
Related to the Regulation of Dietary Supplements: Hearingof the Comm. on Labor and
Human Res., 103d Cong. 60 (1993)
(statement of Sen. Orrin Hatch),
https://archive.org/stream/1egislativeissueOunit/legislativeissueOunit-djvu.txt.
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21
prioritizes access when safety concerns are low. 3 And although
ample criticism persists about the DSHEA-in particular, whether it
4
sufficiently protects consumerS 21 -MoSt critics do not argue that
supplements should be held to the same standards as drugs.
Answering the questions of whether and how to regulate
placentophagy requires us to resolve the same tension. Placentophagy
providers are almost exclusively small business owners selling an
unpatentable product. 2 1 5 If FDA were to regulate placenta pills as a
drug and require premarket review, the product would most likely
disappear from the market-the small placentophagy shops would not
have the resources or incentives to fund the research necessary for
premarket review. 2 16 But the product is largely safe when properly
processed, so effectively banning the product seems like an
overreaction, even if the product's only benefit is placebo, albeit a

Senator Bill Richardson made expressed a similar view: "this issue is all aboutfreedom of choice. The safe use of dietary supplements could save this country billions
of dollars in health care costs each year if adequate information could be given to the
public on labels and pamphlets and the public was allowed to make choices." Id. at 2
(statement of Hon. Bill Richardson).
213. See supra note 212; Gilhooley, Herbal Remedies, supra note 130, at 715 ("If
there is a justification for an alternative system with a lower standard of efficacy, it
would seem to be to allow the consumer the freedom to use a product even when the
efficacy of the product has not been adequately proven so long as use is on an informed
basis, the product is safe, and there are safeguards against indirect harm.").
Opponents, however, abide by the "precautionary principle," whereby new products
should not be introduced when the effects are disputed or unknown.
214. Burke & Page, supra note 109, at 121 ("Since the FDA can attempt to
regulate dietary supplements only after they enter the market, consumers can be at
risk, sometimes great risk, of injury from using unsafe products."); Gilhooley,
Deregulation, supra note 109, at 119 ("A major weakness in DSHEA is that it does not
impose on all dietary supplements the burden and obligation to affirmatively
substantiate their safety.").
215. As of March 2019, almost all of the 751 placentophagy providers listed on
the Placenta Encapsulation website are individual or small groups. Find a Placenta
Specialist, FIND PLACENTA ENCAPSULATION, http://findplacentaencapsulation.coml
find-a-placenta-specialist/ (last visited Mar. 25, 2019).
216. Eisenberg, supra note 97, at 379-80 ("If dietary supplements were subjected
to the same regulatory standards as patented drugs, the most likely result would not
be improved information provision, but the disappearance of these products from the
market."). Encapsulated placenta leads to the same results Eisenberg discusses for
supplements because it cannot be patented. But even if a placentophagy provider could
afford the research, the manufacturer is in a Catch 22: either the research would show
that the perceived benefits of encapsulated placenta are almost entirely attributed to
the placebo effect, in which case FDA would not approve the product, or the
manufacturer would demonstrate efficacy, in which case every placentophagy provider
would be able to competitively use the research to market their products even though
they did not share in the cost of producing it.
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powerful one. 217 Proponents would mobilize, which is exactly what
occurred when Europe attempted to classify placenta as a novel food
that could not be sold until after extensive research was completed. 2 18
There was a public uproar about the impossibility of funding the
research and the impact on accessibility. 2 19 Europe has still not
finalized the regulation, so it is not yet in force. 220
There is another reason to be particularly worried about
overregulation of encapsulated placenta: the potential for a robust doit-yourself ("DIY") alternative. Already some women chose to eat their
placentas raw or encapsulate it themselves-if the product disappears
from the market, even more women will rely on DlY alternatives,
which are much less safe. 22 1 Because self-production is not commerce,
FDA lacks the jurisdiction to regulate it.222 Though rare, encapsulated
placenta is not the only recent technology to raise this issue. 223 As
discussed in Section TV.B below, FDA has recently started regulating
processed, donated stool for fecal transplants-a procedure where
donor feces is implanted into a recipient's colon to treat C. difficile
infections.224 Though similarly unconventional, this new treatment
has helped many people. 22 5 Both products are made exclusively from
human waste-a resource that is easily accessible for those who want

217.
Selander et al., supra note 8, at 105. Placebo is powerful, and the benefits it
produces should not be easily dismissed. The Power of the Placebo Effect, supra note
60.
218. Farr et al., supra note 2, at 407.
219.
See,
e.g., id.; My
Placenta My Choice, PLACENTA NETWORK,
https://www.placentanetwork.comlmy-placenta-my-choicel
(last visisted Mar. 25,
2019); Placenta Service in Europe Should NOT Be Stopped by Novel Food Regulation
(EC)
258/97,
CHANGE.ORG,
https://www.change.org/p/food-standards-agencyplacenta-services-in-europe-should-not-be-stopped-by-novel-food-regulation-ec-25897 (last visisted Mar. 25, 2019).
220.
Farr et al., supra note 2, at 407.
221.
Coyle at al., supra note 2, at 674; Joseph et al., supra note 2, at 478;
McCarthy, supra note 11.
222.
See supra note 88.
223.
In addition to fecal transplants, another example where the possibility of
DIY alternative influenced the extent of government regulation is sperm donation. See
Margaret Brazier, Regulating the Reproduction Business?, 7 MED. L.R. 166, 170, 179
(1999).
224.
FOOD
&
DRUG
ADMIN.,
ENFORCEMENT
POLICY
REGARDING
INVESTIGATIONAL NEW DRUG REQUIREMENTS FOR USE OF FECAL MICROBIOTA FOR
TRANSPLANTATION TO TREAT CLOSTRIDIUMDIFFICILEINFECTION NOT RESPONSIVE TO
STANDARD
THERAPIES
1 (2016),
https://www.fda.gov/downloads/biologicsblood
vaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm488223.p
df [hereinafter FDA, ENFORCEMENT POLICY].
225.
Sachs & Edelstein, supra note 203, at 401.
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to make the product themselves. 226 After initially regulating the
product through premarket review, FDA ultimately backed off.227 One
concern was that if FDA overregulated the product, it might be
exposing consumers to greater risks associated with DIY, amateur
production than the consumers would have been exposed to if the
product were regulated less stringently and available for purchase
from manufacturers. 228 The same concerns exist for encapsulated
placenta. FDA should be very resistant to regulations that could make
a product that is relatively safe when processed properly, dangerous
when consumed raw or after amateur production.
On the other hand, there is little consistency among
placentophagy providers, and the product has been on the market long
enough to know that there are risks associated with improper
handling. Unlike supplements, placentophagy providers are working
with a human tissue, which raises real concerns about the spread of
communicable diseases. There are no guidelines to ensure that their
processing sites are clean, that they do not cross-contaminate
placentas, and that they process placentas in such a way that harmful
bacteria are killed.2 29 Providers can make claims that are misleading
or suggest that placenta pills treat post-partum depression-a disease
230 Some FDA
that can be life-threatening if not properly treated.
regulation is required to protect women from these risks
B. Concerns About the PaternalisticOver-Protectionof Women
Gender is central to the debate of whether to regulate
encapsulated placenta. 231 Women are almost exclusively the product's
consumers and manufacturers, and their reproductive decisions are
frequently in the spotlight. Though the government regulates
healthcare in innumerable ways that affect both genders, laws
surrounding pregnancy are politicized and frequently deprioritize a

Id. at 406.
226.
FDA, ENFORCEMENT POLICY, supranote 224, at 4.
227.
Sachs & Edelstein, supra note 203, at 406.
228.
See Part I (discussing the risks of placentophagy).
229.
See, e.g., Friess, supra note 78 (describing an FDA official's comment that a
230.
placentophagy provider's website was making unsubstantiated health claims).

231. See Charlotte Krolakke, Elizabeth Dickinson & Karen A. Foss, The Placenta
Economy: From Trashed to TreasuredBio-Products, 25 EUR. J. WOMEN'S STUD. 138,
141 (2018) ("Clearly, the placenta economy is gendered. Not only do placentas come
from birthing maternal bodies, particular notions of femininity and understandings of
women's bodies are inscribed in the ways in which placentas move from women giving
birth to female consumers.").
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woman's autonomy for the sake of a religious- or value-based goal. 2 32
As a result, many women are understandably sensitive to the state's
intrusion into medical decisions that only women encounter. Laws
that purport to promote a woman's safety or informed consent are
often pretext for legislation intended to limit access to reproductive
health services, such as abortion, 233 contraception, 2 3 4 natural labor, 2 35
and even participation in medical research while pregnant. 236
Abortion is the obvious example where women's reproductive
choices are limited by the government. But over the past five decades,
the state has inserted itself increasingly into women's decisions over

childbirth:
There are significant regulatory limits on reproductive choices
during pregnancy. Regulations surrounding the use of
midwives are increasingly restrictive. Moreover, women who
want to undergo natural childbirth are increasingly restricted
from doing so because of hospital regulations prohibiting
natural birth after C-sections, breach births, and other highrisk vaginal deliveries. Home births are increasingly rare as
doctors and midwives cannot obtain insurance coverage for
attending such births and because of explicit restrictions. The
mandatory use of fetal monitoring devices in hospitals is at an
all-time high, even when not medically indicated. Thus,

232.
Donley, supra note 46, at 61, 75 (discussing how FDA's regulation of
pregnant women in research and over-the-counter Plan B purports to protect women,
but is really a political decision); Pamela Laufer-Ukeles, Reproductive Choices and
Informed Consent:FetalInterests, Women's Identity, and RelationalAutonomy, 37 AM.
J.L. & MED. 567, 582 (2011) ("The focus on women and their needs [in the context of
abortion] has been surrendered in pursuit of political aims."); Sylvia A. Law,
Childbirth:An Opportunity for Choice That Should Be Supported, 32 N.Y.U. REV. L.
& Soc. CHANGE 345, 363 (2008) ("Traditions of paternalism and disrespect for patient
choice are particularly strong in relation to childbirth and reproduction.").
233.
Laufer-Ukeles, supra note 230, at 592-93 (describing "informed consent"
legislation as "unabashedly biased and reflect[ing] ideological interests of the state as
long as it is deemed not misleading or untruthful"); Olga Khazan, Planningthe End of
Abortion,
ATLANTIC
(July 16,
2015),
https://www.theatlantic.com/politics/
archive/2015/07/what-pro-life-activists-really-want/398297/
(describing
how
Americans United for Life proposes draft legislation for state legislatures to introduce,
some of which are purported to protect women's safety and consent).
234.
Donley, supra note 46, at 61.
235.
See, e.g., Laufer-Ukeles, supra note 230, at 587 (describing the "regulatory
limits on reproductive choices during pregnancy" including restrictions on natural
childbirth and the rise of the use of the C-section).
236.
Donley, supra note 46, at 61.
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for
options
women's
increasingly imited. 237

non-interventionist

births

are

Institutional or state rules now govern most aspects of the childbirth
process. 2 3 8 To the extent that a woman's plans for her child's birth
depart from the conventional or institutional expectation, she may
239
feel varying degrees of pressure to conform.
These rules are typically justified as necessary to protect women,
and it is true that maternal mortality dramatically declined during
2 40
But
the time period that women started giving birth in hospitals.
they can also work to women's detriment. For instance, the United
States has experienced a dramatic increase in the number of births
resulting in cesarean section, which are often not in the best interest
of the mother.24 1 One-third of U.S. births are through cesarean
section, even though the World Health Organization contends that
caesarean rates higher than 10% do not reduce maternal or infant
mortality. 242 And caesarian deliveries greatly increase complications
243
By comparison, the
and negatively impact maternal recovery.

237. Laufer-Ukeles, supra note 232, at 587.
See id.; Dara E. Purvis, The Rules of Maternity, 84 TENN. L. REV. 367, 396
238.
(2017) ("Many commentators have described birth as increasingly medicalized in
recent years and correspondingly increasingly controlled by doctors rather than the
laboring mother.").
See, e.g., Laufer-Ukeles, supra note 232, at 588 (describing the growing
239.
"pressure toward intervention" in childbirth, which has limited free choice); Purvis,
supra note 238, at 397 ("Not only are women pressured and sometimes coerced by their
doctors to deliver by c-section, particularly if past deliveries were also by c-section, but
the state has repeatedly either punished women for refusing to have a c-section if the
baby is arguably harmed by that decision, or actually ordered women to undergo the
procedure.").
Neal Devitt, The Transition from Home to Hospital Birth in the United
240.
States, 1930-1960, 4 BIRTH & FAM J. 47, 47 (1977).
See e.g., Laufer-Ukeles, supra note 232, at 587-88; Purvis, supra note 238,
241.
at 397; Farah Diaz-Tello, When the Invisible Hand Wields a Scalpel: Maternity Care
in the Market Economy, 18 CUNY L. REV. 197, 203 (2015) ('The health risks of
cesarean surgery are mostly borne by the birthing person, and largely deferred into
subsequent pregnancies . . . .").
Diaz-Tello, supra note 241, at 203.
242.
AM. COLL. OBSTETRICIANS & GYNECOLOGISTS & SOC'Y FOR MATERNAL243.
FETAL MED., OBSTETRIC CARE CONSENSUS: SAFE PREVENTION OF THE PRIMARY
CESAREAN DELIVERY 1-3 (2014), https://www.acog.org/-/media/Obstetric-Care1 9 4 3 4 4 58 3
2
(noting that "for most
0
Consensus-Series/ocOOl.pdf?dmc=l&ts=201710 3T
pregnancies, which are low-risk, cesarean delivery appears to pose greater risk of
maternal morbidity and mortality than vaginal delivery" and that "the downstream
[caesarian risks] are even greater because of the risks from repeat cesareans in future
pregnancies"); Nancy Ehrenreich, The Colonization of the Womb, 43 DUKE L.J. 492,
537 (1993) ("Protecting a fetus often entails imposing certain risks on the woman
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Nordic countries perform roughly half as many caesarian sections as
the United States,244 but their infant mortality rates are also roughly
half of the rates in the United States. 24 5 Furthermore, four to five
times more women die in the United States from childbirth-related
complications than in Finland, Sweden, and Iceland. 2 4 6 In other
words, American women are subject to the complications, side-effects,
and risks of cesarean section twice as often, but they and their
children still have much worse outcomes.
Some women in the United States who seek to deliver vaginally
are shamed, threatened, or even coerced by courts and hospitals into
undergoing a caesarian section against their will or preference. 247
This is despite the fact that reasonable people can disagree about
whether a caesarian section is truly medically necessary. 248 Poor
women of color are the most affected by such terrible treatment and
also the most likely to die in childbirth.249 Regardless of one's views
on the movement towards natural childbirth, it is not clear that the
state is always acting in the woman's best interest in recommending
(or coercing) an interventionist birth.
The regulation of midwifery presents another apt example of
childbirth regulation that may actually harm women, despite being

carrying it; a Cesarean section, for example, is at least twice as likely as a vaginal
birth to result in the death of the mother. Yet this risk becomes irrelevant if the
cultural norm already prescribes that she be willing to sacrifice anything and
everything for her children (born or unborn).").
244.
See Caesarean Sections, in HEALTH AT A GLANCE 2017: OECD INDICATORS
180, 180
(2017),
https://www.oecd-ilibrary.org/docserver/health-glance-2017-66en.pdfexpires=15 3 0 7 2 2899&id-id&acename=guest&checksum-635387E
B7ED8A072A3A814979C353EOO (noting that Finland, Sweden, the Netherlands, and
Iceland have caesarian rates between 15 and 17%).
245. Infant Mortality Rates, OECD, https://data.oecd.org/healthstat/infantmortality-rates.htm (last visited Mar. 25, 2019).
246. See WHO et al., Maternal Mortality Ratio (Modeled Estimate, Per 100,000
Live
Births),
WORLD
BANK
(2015),
https://data.worldbank.org/indicator/

SH.STA.MMRT.
247.
See, e.g., Diaz-Tello, supra note 241, at 222-25; Purvis, supra note 238, at
397-402; see also Ehrenreich, supra note 243, at 500-01 (discussing the intersection
of race and gender as it relates to forced cesarean sections); Law, supra note 232, at
359 ("In short, women who have had C-sections are commonly denied the freedom to
choose vaginal delivery for subsequent births, even though the medical evidence
suggests that the choice is complex, but reasonable.").
248.
Law, supra note 232, at 359.
249.
Ehrenreich, supra note 243, at 501 ("The pattern of behaviors it identifies
could occur during any woman's labor, and yet the vast majority of court-ordered Csections have involved poor women of color."); Danielle Thompson, Midwives and
Pregnant Women of Color: Why We Need to Understand Intersectional Changes in
Midwifery to Reclaim Home Birth, 6 COLUM. J. RACE & L. 27, 38 (2016).
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purported to help them. Like placentophagy, women are historically
both the exclusive consumers and providers of midwifery services. In
1900, more than half of American women gave birth through a
2 50
State
midwife; by 1950, 88% of women delivered in a hospital.
regulation played a huge role in this change, and many have criticized
this development as constituting the "medicalization" of childbirththe paradigm shift that changed the perception of birth as a natural
25
process to a pathology requiring medical intervention. 1 One of the
main culprits of this change was states' criminalization of the
252
unlicensed practice of medicine around the turn of the century.
Although the alleged aim of licensing laws was to protect the public,
the laws also allowed physicians to reduce the number of providers
253
competing for clients, thereby increasing demand for their services.
And physicians, largely due to this anti-competitive motivation, began
to sue midwives under licensing laws to increase their customer
base. 25 4 This undoubtedly contributed to the mass migration towards
255
hospital labor.
As a result, childbirth quickly changed from a women-centered
256
to a maleritual where "women wanted and needed only each other"

Stacey A. Tovino, American Midwifery Litigation and State Legislative
250.
Preferences for Physician-Controlled Childbirth, 11 CARDOZO WOMEN'S L.J. 61, 67
(2004).
Wolfson describes the "medicalization" of birth as referring to three
251.
phenomena: "first, the elimination ofthe midwife as a primary birth attendant; second,
the shift in the location of birth from home to hospital; and third, the use of
increasingly invasive medical interventions during the birth process." Charles
Wofison, Midwives and Home Birth: Social, Medical, and Legal Perspectives, 37
HASTINGS L.J. 909, 909 n.3 (1986) (internal citations omitted); see also Purvis, supra
note 238, at 396.
See Thompson, supra note 249, at 32.
252.
See Susan Corcoran, To Become A Midwife: Reducing Legal Barriersto Entry
253.
into the Midwifery Profession, 80 WASH. U. L.Q. 649, 656-57 (2002) ("The primary
justification for licensure is protection from unqualified, incompetent practitioners.
However, licensure of midwifery, as in all professions, also often serves an
anticompetitive purpose."); Walter Gellhorn, The Abuse of OccupationalLicensing, 44
U. Cm. L. REV. 6, 11 (1976) ("[L]icensing has been eagerly sought-always on the
purported ground that licensure protects the uninformed public against incompetence
or dishonesty, but invariably with the consequence that members of the licensed group
become protected against competition from newcomers.").
See, e.g., Tovino, supra note 250, at 85, 101-03; Thompson, supra note 249,
254.
at 33-35.
See Thompson, supra note 249, at 32 (describing the shift in the early
255.
twentieth century towards hospital births).
Id. at 30 ("Pre-hospital birthing was thus something of a feminist endeavor
256.
in which women wanted and needed only each other, because they knew that their
specific female experience made them more equipped than any male physician to aid
a woman in a non-complicated labor and delivery.").
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dominated enterprise. "As hospital births grew in prominence and
male physicians began to attend more births, the 'presence of this
male authority figure changed the power structure in the [birthing]
room.' This anti-feminist power shift denied women-who were
already seen as socially inferior and less capable than men-authority
over their own bodies and births." 2 57 Although delivering in a hospital
with the assistance of an OBGYN has many benefits and may be the
only feasible option for complicated pregnancies, many women can
safely deliver with a midwife either at home, in a birthing center, or
at a hospital. 258
Women who consume their placentas discuss their aversion to the
medicalization of birth, which they often associate with patriarchal
overtones. 259 Elizabeth Dickinson and her collaborators collected
stories of women who participated in placentophagy to understand
their motivations. She noted that "[miost of the supporters see
obstetrics as a dysfunctional childbirth model that disciplines the
female body and causes risk to mother and child." 2 60 For instance, one
supporter lamented the "othering of women's bodies where we make
everything gross-breastfeeding,
menstruation,
birth-it's all
gross." 26 1 Another criticized a reality in which "[mlost of OBGYNs are
men; women aren't in charge of birth anymore." 262 In collecting these
women's stories, Dickinson concluded that "supporters have come to
reject what Foucault (1989) called the 'medical gaze,"' where "health
care professionals (mostly male doctors) in hospitals began to exert
power and central authority over the body, relying on empirical
observations and analyses to 'treat' the body, often regardless of what
patients think or want." 2 6 3 She observed that women reject the
medicalization
of
childbirth-including
the
disgust
with
placentophagy-as a way of empowering themselves and regaining
control over their bodies. 2 6 4 These women are seeking to exercise their
autonomy in a system that has increasingly limited their choices.

257.
Id. (internal citation omitted) (alteration in original).
258.
See, e.g., Jessica Brown, The Fightfor Birth: The Economic Competition That
Determines Birth Options in the United States, 52 U.S.F. L. REV. 1, 6-8 (2018): Ruth
Zielinksi et al., Planned Home Birth: Benefits, Risks, and Opportunities, 7 INTL J.
WOMEN'S HEALTH 361, 375 (2015).
259.
Dickinson et al., supra note 35, at 123-24.
260.
Id. at 121.
261. Id. at 123.
262. Id. at 121.
263.
Id. at 123.
264.
See id. at 124 ("The resistance to acting appropriately as per the tenants of
patriarchal Western medicine and the medical gaze (e.g., give birth in a hospital, do
what the obstetrician tells you, and certainly do not eat your placenta) can be
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Some may criticize these women for finding benefit in a product
that has no proven effect, for essentially being fooled by a placebo. But
this observation is misguided and inherently gendered in this context.
The placebo effect itself can produce very strong improvements, and
it is not uncommon for physicians to proscribe safe, but unproven,
interventions they hope might benefit the patient, especially when
265
Consumers frequently use
traditional treatments have failed.
products or interventions that have no proven benefit over placebo,
26
including acupuncture and supplements. 6 But as they are safe, the
government does not prevent consumers from indulging in the fantasy
to their benefit. In fact, the government has at times gone further and
even supported certain placebos, like providing battleground
267
Encapsulated
acupuncture for pain management in soldiers.
placenta is no different, and treating it otherwise creates a double
standard for placebo products that only women consume.
FDA has previously been criticized for creating a separate
standard for products that only women use and that relate to
reproduction. In 2013, the Eastern District of New York chastised
FDA for failing to approve Plan B contraception for girls under
seventeen without any scientific basis: "Because the Secretary's action
was politically motivated, scientifically unjustified, and contrary to
agency precedent, it cannot provide a basis to sustain the denial of the
Citizen Petition." 268 This case concluded a years-long struggle with

empowering because mothers can exert control by doing what they want with their
placentas, regardless of 'lack of proof."').
See, e.g., The Power of the Placebo Effect, HARV. MEN'S HEALTH WATCH
265.
https://www.health.harvard.edulmental-health/the-power-of-the2017),
(May 1,
placebo-effect; Felicity L. Bishop, Lizzi Aizlewood, Alison E.M. Adams, When and Why
Placebo-PrescribingIs Acceptable and Unacceptable:A Focus Group Study of Patients'
Views, 9 PLOS ONE 1, 7 (2014) ("[A placebo m]ight relieve [the patient's] pain when
nothing else is available to do that."); P. Lichtenberg, U., Heresco-Levy & U. Nitzan,
The Ethics of the Placebo in Clinical Practice,30 J. MED. ETHICS 551, 552 (2004).
See, e.g., David Colquhoun & Steven P. Novella, Acupuncture Is Theatrical
266.
Placebo, 116 ANESTHESIA & ANALGESIA 1360, 1360 (2013) ("[A]cupuncture quickly
became popular in the West . . . [although] the benefits of acupuncture are likely
nonexistent, or at best are too small and too transient to be of any clinical significance.
It seems that acupuncture is little or no more than a theatrical placebo."); Nicholas
Bakalar, Placebo Beats Supplements for Arthritis Pain, N.Y. TIMES (Jan. 26, 2017),
https://www.nytimes.com/2017/01/26/well/Uive/placebo-beats-supplements-for-arthriti
s-pain.html.
See e.g., Alex Berezow, Acupuncture: Is It Ethical to Give a Combat Soldier
267.
a Placebo for Pain?, AM. COUNCIL ON SCI. & HEALTH (Apr. 16, 2018),
https://www.acsh.org/news/2018/04/16/acupuncture-it-ethical-give-combat-soldier-pla
cebo-pain-12846.
Tummino v. Hamburg, 936 F. Supp. 2d 162, 192 (E.D.N.Y. 2013); see also
268.
Tummino v. Torti, 603 F. Supp. 2d 519, 546 (E.D.N.Y. 2009), amended sub nom by
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the recalcitrant agency determined to prevent minors from accessing
Plan B despite lacking any legitimate safety concerns. 269 And now, the
ACLU is suing the agency for not letting pharmacies in rural locations
provide abortion pills; instead, patients must obtain them at a medical
facility. 270 The agency has also been accused of prioritizing fetal over
maternal harms in how it regulates the labels of pharmaceuticals that
might be consumed in pregnancy. 271 The agency should take care to
avoid another instance in which it overregulates women's
reproductive choices. If FDA regulates encapsulated placenta to the
point it disappears from the market, it will perpetuate the experience
of consumers who already feel that women's autonomy over their
reproductive decisions is curtailed by governmental and institutional
forces that they associated with the patriarchy.
Of course, even the strictest proponents of female autonomy do not
oppose all regulations surrounding reproduction and childbirthwomen cannot make informed, autonomous decisions when providers,
manufacturers, or institutions are not held to a minimum floor of
honesty and competence. The medical setting involves an information
asymmetry that can make all individuals, including women,
vulnerable without some government involvement. 2 72 Pamela LauferUkeles resists the perception that autonomy and protection are
mutually exclusive. 273 Instead, she argues that we should "facilitat[e]
women's choices within the context of some legislative limits"-in
other words, regulations need to promote autonomy by both
maximizing choice and minimizing exploitation. 2 74 Her approach
recognizes the failures of two different feminist critiques of
government regulation (or lack thereof):
Those who have previously examined or attempted to improve
women's autonomy in reproductive decision making in the

Tummino v. Hamburg, 936 F. Supp. 2d (E.D.N.Y. 2013) ("Indeed, the evidence strongly
suggests that even the decision to permit the OTC sale of Plan B to women over the
age of 18 was made solely to facilitate the confirmation of Dr. von Eschenbach as
Commissioner of the FDA.").
269.
Tummino v. Hamburg, 936 F. Supp. 2d at 164.
270.
Sarah McCammon, ACLU Sues to IncreaseAccess to Abortion Pill, NPR (Oct.
3, 2017), http://www.npr.org/2017/10/03/555310966/aclu-sues-to-increase-access-toabortion-pill?utm-source=facebook.com&utmmedium=social&utm-campaign=npr&
utmterm=nprnews&utmcontent=202703.
271.
Donley, supra note 46, at 68-75.
272.
See Diaz-Tello, supra note 241, at 210 ("[The provider-patient relationship
is one that is characterized by an asymmetry of information and power.").
273.
Laufer-Ukeles, supra note 232, at 572.
274. Id.
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medical context have attacked from one of two directions. One
approach is to emphasize the rights of the woman as an
individual, irrespective of the fetus....
Others attack reproductive choices as being too unregulated
and urge an increase in legislation to improve the safety and
health of gestating women....
...

On the one hand, leaving women alone does not do enough

to support autonomy. On the other hand, regulating and
restricting those choices can go too far in undermining
autonomy. 2 75
Laufer-Ukeles's assessment is well taken. Respecting women means
neither under nor over regulating them. Women deserve protection
without paternalism.
When it comes to the regulation of encapsulated placenta, FDA
should aim for a middle ground approach where women benefit from
a regulatory floor that mitigates the risk of misinformation and
contaminated products, but that ultimately protects women's
autonomy to make decisions over their own childbirth experience.
This approach would ensure that encapsulated placenta providers are
not, for instance, surreptitiously mixing women's placentas together
or processing placentas in unsanitary conditions; however, it would
not regulate the product so stringently that the small businesses could
not comply with the regulations, driving encapsulated placenta from
the market entirely.

Both policy concerns discussed in this Part suggest that regulation
of encapsulated placenta is warranted, but not so much as to render
to product unavailable. Taking these considerations into account
would ask the agency to regulate the product according to a category
that both establishes a minimum floor with regard to risk, but also
ensures the product's availability. In Part IV, I argue that Intended
Use would produce a bad result from a policy perspective-it would
lead to the product's under or overregulation. In such cases, FDA will
occasionally use its enforcement discretion to regulate the product in
a manner that best protects consumer safety and access. I think it
should do so here. I argue below that FDA should regulate
encapsulated placenta as both a 361 HCT/P and a supplement. Such
275.

Id. at 571-73.
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regulation would best effectuate the policy goals underlying FDA
categories and balance FDA's competing priorities. It would be a novel
categorization-I do not know of any other product regulated under
these two categories-but one that the agency might use for various
other new technologies involving biologic substances that do not
require premarket review to protect consumers.
IV. TOWARD A BALANCED REGULATION OF ENCAPSULATED PLACENTA
FDA's typical mechanism for classifying mixed productsIntended Use-would create a problematic result in the case of
encapsulated placenta. Either it would classify encapsulated placenta
as a drug or biologic, which would overregulate it to the point that it
disappears from the market, or as a supplement, which would fail to
prevent the types of harms that encapsulated placenta has recently
caused. I argue below that FDA should use its enforcement discretion
to regulate encapsulated placenta as both a supplement and a 361
HCT/P. These regulations combined would ensure that women are
protected from the worst risks of encapsulated placentaunsubstantiated disease claims and the improper processing of
tissue-without creating insurmountable entry barriers for the
product. It therefore strikes an appropriate balance in protecting
women without eliminating their choices.
A. Intended Use Would Lead to the Wrong Result
As explored in Section II.B, Intended Use does not produce clear
results for encapsulated placenta. Under the most likely scenario,
FDA would find that encapsulated placenta is a human tissue that
fails to meet the 361 HCT/P requirements and must therefore be
regulated as a biologic requiring premarket review. It's possible,
however, that if encapsulated placenta manufacturers were
marketing their products as supplements without making disease
claims, FDA would only require them to meet the supplement
regulations. This is the approach the agency appears to be taking (at
least in the short term) for probiotics, which should also technically
be regulated as biologics under FDA's regulatory scheme.
Neither of these options, however, would create the optimal
outcome from a policy perspective. Supplement regulations would
underregulate the product, opening women up to unnecessary risks.
Though supplement regulations prevent the type of harm associated
with unsubstantiated disease claims, they would fail to prevent the
types of harms associated with improper handling of human tissue.
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For instance, the supplement regulations would not stop
manufacturers, like the ones in Miami, from mixing various women's
276
They would also not
placentas together before distributing them.
stop manufacturers from undercooking the product and causing
277
bacterial infections like the one the CDC reported. And it would not
stop the cross contamination of tissues that might lead to a spread of
278
Human tissues are not
diseases like HIV, Zika, and hepatitis.
vitamins; processing them involves compliance with particular
279
As a result, supplement
conditions that reduce contamination risks.
regulations alone are insufficient.
On the other hand, the biologic regulations, which require
premarket review, will overprotect women to their detriment.
Encapsulated placenta, like most supplements, would be unable to
2
benefit from either patent or regulatory exclusivity. 80 Thus, if it were
regulated as a drug or biologic, the regulation would act as an effective
ban as manufacturers would have no incentive to incur the cost
28 1
And exclusivity
associated with new drug or biologic approval.
would not make sense for encapsulated placenta. Unlike most drugs
and supplements, which can be mass-produced and sold nationally
under a monopoly, encapsulated placenta can only be safely made
See FloridaDepartment of Health, supra note 67.
276.
Buser et al., supra note 65, at 677.
277.
Farr et al., supra note 2, at 405.
278.
See id.
279.
Because the product is already on the market, manufacturers could not meet
280.
the novelty requirement for patent protection. See Abbott, supra note 193, at 68-73.
And while encapsulated placenta manufacturers could apply for FDA's regulatory
exclusivity if it were approved as a new drug, FDA has generally chosen to not enforce
that exclusivity for products already on the market. See Sachs & Edelstein, supranote
121, at 404. To explain why the lack of exclusivity matters, consider this explanation
from Eisenberg: If FDA were to tell the placentophagy industry that it must obtain
premarket approval, encapsulated placenta would be removed from the market until
the industry produced sufficient research to demonstrate "it [was] safe and effective."
Eisenberg, supra note 97, at 379 (describing a similar hypothetical). But encapsulated
placenta is not patentable or guaranteed regulatory exclusivity. Thus, even if a
manufacturer funded the research that proved encapsulated placenta's safety and
efficacy, it would re-enter the market without a monopoly and every other
placentophagy manufacturer (none of whom shared in the cost of the research) could
use the new data to promote their product. In this scenario, the manufacturer would
not be able to recoup any of the money it spent on the research, and competition could
still drive it out of business. Furthermore, the funded study might actually show that
encapsulated placenta is "unsafe," or more likely, "ineffective." Then, the
manufacturer would lose the money it invested in research, fail to obtain FDA
approval, and still be forced to exit the market. Manufacturers would therefore have
nothing to gain by funding the research and attempting to gain drug approval and
would instead accept that they were forced out of the market. See id.
281. Eisenburg, supra note 97, at 379.
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individually. It is a product made from a woman's own tissue, and as
a result, if one manufacturer received exclusivity, it could not take
advantage of it by cornering the national market. Rather, exclusivity
in this context would only function to make the product available to
the women within physical proximity to the exclusive provider. 282
Premarket review is simply an ill-fitting scheme for this product.
Of course, if encapsulated placenta raised serious safety concerns,
it should be inaccessible. But as I argue below, FDA can remove the
safety risks while maintaining the product's accessibility. Creating
the ideal solution involves examining the product's genuine risks and
narrowly tailoring regulations to neither over- nor under-protect
women. Below, I explore the risks of encapsulated placenta and the
regulations designed to prevent those exact risks. I conclude that the
supplement and 361 HCT/P regulations combined would sufficiently
protect women without removing access.
B. FDA Should Use Its Discretion to Regulate EncapsulatedPlacenta
as Both a Supplement and 361 HCT/P
The main types of harms that encapsulated placenta risks are
(1) the spread of communicable diseases caused by the improper
handling of human tissue, and (2) unsubstantiated disease claims.
These are the types of harms that the 361 HCT/P and supplement
regulations are designed, respectively, to prevent. Furthermore,
because encapsulated placenta contains a new dietary ingredient,
regulating it as a supplement would also ensure that it meets
minimum safety standards. Neither of these regulations, however,
require the intense premarket review of drug or biologic regulations
(and the corresponding efficacy requirements), and as a result, would
not cause the product to disappear from the market. For FDA to
regulate encapsulated placenta in this way, it would need to exercise
its enforcement discretion, which it has done in the past for similarly
novel products. To effectuate the policy concerns discussed in Part III,
the agency should take the same approach here.

282.
This inability to "scale up" is one of the things that has led to the more
minimal regulations for blood and fecal transplants. Sachs & Edelstein, supra note
121, at 409, 414.
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1. The 361 HCT/P and Supplement Regulations Would Adequately
Protect Consumers
The best way to protect consumers from a particular product
without overprotecting them is to match a product's risks with
regulations intended to mitigate those exact risks. This approach
would not work when a product's risks are unknown, but given that
encapsulated placenta has been on the market for decades (and
recently studied in the literature), we have some confidence in our
knowledge of its risks-namely, the spread of communicable diseases
and unsubstantiated claims about the product's ability to treat or
prevent disease. 283 The 361 HCT/P and supplement regulations are
aimed at mitigating those specific risks without requiring premarket
approval, and therefore regulating encapsulated placenta under these
categories should strike the appropriate balance between FDA's
competing goals.
a. Improperly Handled Tissue
As discussed in Part I, there are risks associated with improperly
prepared placenta, including the spread of communicable disease.
First, as highlighted by the CDC report, when placentophagy
providers fail to properly store and heat the placenta, it can contain
harmful bacteria that may cause infections in either the mother or
breast-feeding infant. 284 Second, providers working with multiple
placentas may fail to properly separate the tissues and sanitize their
instruments, which can result in the spread of viruses between the
placentas, like HIV, hepatitis, and Zika. 28 5 Third, providers could mix
different women's tissues in a mass production scheme, like the plot
FDA foiled in Miami in 2008.286

The 361 HCT/P regulations seek to prevent the spread of
communicable diseases, including those transmitted by bacteria and
viruses. 287 They require manufacturers to abide by donor eligibility
requirements, like donor screening and testing, when the donor is
different from the recipient; follow good tissue practices that prevent
spoliation, contamination, and the spread of communicable diseases;
and ensure that all manufacturers have registered with FDA so that

283.
284.
285.
286.
287.

See supra text accompanying notes 62-77.
See Part I; Buser et al., supra note 65, at 677.
Farr et al., supra note 2, at 405.
See Part I; FloridaDepartment of Health, supra note 67.
21 C.F.R. § 1271.150(a) (2018).
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the agency can inspect for compliance. 288 FDA has stated that the
primary purpose of these regulations is to increase "public confidence
in [HCT/P] safety, by preventing the introduction, transmission and
spread of communicable disease." 2 8 9
In particular, 361 HCT/P regulations require manufacturers to
"recover, process, store, label, package, and distribute HCT/Ps. .. in
a way that prevents the introduction, transmission, or spread of
communicable diseases." 290 HCT/Ps must be stored "at an appropriate
temperature." 291
These
requirements
would
ensure
that
placentophagy providers (1) properly refrigerate the tissue until it is
ready for processing to prevent spoliation and (2) properly heat the
placenta to temperatures necessary to kill sufficient bacteria to
prevent the spread of bacterial infections. These two precautions
alone would help prevent infections like the one CDC reported. 292
Furthermore, any "establishment that processes HCT/Ps" must do
so "in a way that does not cause contamination or cross-contamination
during processing, and that prevents the introduction, transmission,
or spread of communicable disease through the use of the HCT/P."293
The facility must also "establish and maintain procedures for
cleaning, sanitizing, and maintaining equipment to prevent
malfunctions, contamination or cross-contamination. .. ."294 These
regulations would ensure that placentophagy providers keep tissues
separated and sanitize any instruments or surfaces that come into
contact with multiple tissues. Finally, the 361 HCT/P regulations also
specifically prevent tissue pooling: "Human cells or tissue from two or
more donors must not be pooled (placed in physical contact or mixed
in a single receptacle) during manufacturing." 295 This regulation
would prevent the mass placenta encapsulation schemes, like the one
in Florida FDA foiled in 2008.296 Taken together, the 361 HCT/P
regulations could prevent the risk of communicable disease that
encapsulated placenta presents. The product should therefore be
regulated under this scheme.

288.
Id. § 1271.
289.
FDA, REGULATION OF HUMAN CELLS, TISSUES, AND CELLULAR AND TISSUEBASED PRODUCTS (HCT/Ps), supra note 147, at 3.
290.
21 C.F.R. § 1271.145 (2018).
291.
Id. § 1271.260(b); see also 21 C.F.R. § 1271.260(e) (2018).
292.
See Buser et al., supra note 65, at 677.
293.
21 C.F.R. § 1271.220(a) (2018).
294.
Id. § 1271.200(b).
295.
Id. § 1271.220(b).
296.
See FloridaDepartment of Health, supra note 67.
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b. Unsubstantiated Disease Claims
Another risk of encapsulated placenta is that manufacturers will
make unproven disease claims in marketing their products. The
supplement regulations recognize that disease claims are special and
should not be made without first having their accuracy scrutinized
through premarket review. FDA has concluded that disease claims
"can pose serious risks to consumers" by inducing them "to substitute
ineffective or less effective treatments for proven ones, especially if
297 A product's
the disease involved is serious or life-threatening."
claims that it will prevent cancer, cure osteoporosis, treat heart
disease, or mitigate the symptoms of depression meet consumers
where they are most vulnerable, seriously influencing purchasing
decisions. 298 As a result, FDA worried that "patients cannot safely
evaluate on their own" the "claims that might relate to serious health
conditions." 299 To prevent manufacturers from taking advantage of
consumers' often desperate desire to fix the pain and suffering caused
by disease, the agency only allows disease claims when their accuracy
has been proven through premarket review of new drugs and
biologics.30 0
Structure, function, and nutrient deficiency claims, by contrast,
are general statements about how supplements may affect the human
body. The claims that, for instance, soluble fiber improves the
functioning of the digestive tract; that calcium builds strong bones; or
that iron helps with an iron deficiency do not make the kinds of
promises that consumers might be desperate to hear. Furthermore,
consumers are less likely to interpret the statements as directed
specifically at them-unlike structure, function, and nutrient
deficiency claims, disease claims are more individualized to
consumers who have been diagnosed with a particular condition.
Given the important distinctions between these two types of claims,
the supplement regulations permit structure, function, and nutrient
301
deficiency claims to appear on supplement labels.
Regulations on Statements Made for Dietary Supplements Concerning the
297.
Effect of the Product on the Structure or Function of the Body, 65 Fed. Reg. 1000, 1006
(Jan. 6, 2000) (to be codified at 21 C.F.R pt. 101).
See Gilhooley, Herbal Remedies, supra note 130, at 687.
298.
Regulations on Statements Made for Dietary Supplements Concerning the
299.

Effect of the Product on the Structure or Function of the Body 65 Fed. Reg. at 1011
(Jan. 6, 2000) (to be codified at 21 C.F.R pt. 101).
300. See id. at 1023.
301 Nevertheless, a manufacturer can only make structure, function, or nutrient
deficiency claims if it has substantiation that the claim is truthful and not misleading.
This evidentiary standard is notably less stringent than what is required to prove
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Like
supplement
manufacturers,
encapsulated
placenta
manufacturers should be prohibited from making disease claims
unless the manufacturers can prove efficacy through premarket
review. Placenta products that make disease claims should be taken
off the market. The most common disease claim that encapsulated
placenta manufacturers make is that the product can treat or mitigate
the symptoms of post-partum depression or post-partum mood
disorders. This claim is concerning. Very little evidence beyond selfreporting demonstrates that encapsulated placenta is more effective
than placebo at causing any purported benefit.3 02 And though placebo
can be quite powerful, 30 3 it could also cause women with serious postpartum depression to forgo pharmacological treatment. 304 Untreated
postpartum depression can cause serious physical and emotional
harm to both the mother and child.3 05 This is exactly the type of
disease claim that comes with serious risks and should not be made
by encapsulated placenta manufacturers unless future research
clearly corroborates it. To the extent that manufacturers want to
market encapsulated placenta with structure, function, or nutrient
deficiency claims, however, they may do so as long as they follow
FDA's guidelines, including that the claim be substantiated and
properly disclaimed.306
c. Minimum Safety Assurances
Finally, supplement regulations would also ensure a minimum
standard of safety. Because encapsulated placenta was not on the
market in 1994 and is not currently in the food supply, the dietary
supplement regulations would require manufacturers to obtain new

&

accuracy of disease claims under premarket review, which reflects the reduced risk
that structure, function, and nutrient deficiency claims will induce irrational decisionmaking or be beyond the ability of consumers to evaluate. Guidance for Industry:
Structure/FunctionClaims, supra note 128.
302 See Young, Pilot 2, supra note 57, at e268.
303 See supra, Section III.B; Selander et al., supra note 8, at 105.
304 See, e.g., Bakalar, supra note 266.
305 See, e.g., Shelley Doucet et al., Differentiation and Clinical Implications of
PostpartumDepression and PostpartumPsychosis, 38 J. OBSTETRIC, GYNECOLOGIc
NEONATAL NURSING 269, 269-70 (2009) ("If left untreated, both disorders can result
in negative consequences including the risk of recurrent psychiatric illness, marital
dysfunction, suicide, and infanticide. Research on PPD has shown that the infant is at
risk for behavioral problems, delayed cognitive or psychosocial development, and
impaired mother-infant bonding." (internal citations omitted)).
306 See Section II.A.2.
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dietary ingredient approval. 307 Unlike premarket review, which takes
decades to prepare the research necessary for a successful application,
an NDI application must only be submitted seventy-five days before
3 08
Once those seventy-five days have
the product enters the market.
unless FDA denies the
marketed
be
can
product
the
passed,
does not need to wait
manufacturer
the
application-in other words,
309
for approval.
As part of the application process, the manufacturer must
demonstrate that it is "reasonably . . . expected to be safe under the
3 10
conditions of use recommended or suggested in the labeling."
Encapsulated placenta manufacturers should be able to make this
showing. 311 The product has been on the market and consumed safely
3 12
And more,
by women when properly processed for over a decade.
consuming
women
on
research teams have started conducting studies
their placentas, none of which have reported adverse events for the
women or their children. 3 13 The 361 HCT/P regulations would only
make these products safer. Though FDA rejected sheep placenta as
an NDI in 2002, the landscape and research has entirely changed in
the past fifteen years, and with only minimal effort, an encapsulated
placenta manufacturer could submit an application that was of much
higher quality than the one FDA reviewed in 2002.314 Of course, if new
evidence were to emerge suggesting that properly processed
encapsulated placenta presented serious safety concerns, it would call
into question the assumptions of this Article, and the agency should
deny NDI approval.
In combination, the 361 HCT/P and supplement regulations
should adequately protect women and their children without
overregulating a product they exclusively produce and consume. The

307. Manufacturers would need to prove that placenta is a "a dietary substance
for use by man to supplement the diet by increasing total dietary intake," likely
pointing to the vitamins and minerals it contains. New DietaryIngredients, supra note
112.
308. Id.
309. Id.
310. Id.
Of course, the outcome is not predetermined, nor should it be. If FDA cannot
311.
the product meets minimum safety standards, then the product should
that
conclude
not be sold.
See supra Part I.
312.
See supra Part I.
313.
See NDI 139 - Sheep Placenta from YAT CHAU (USA) INC., supra note 117,
314.
at 1-2 (listing the reasons why the proposal was rejected in 2002). As noted above,
FDA's letter explained that the applicant failed to comply with the basic requirements
of the application process.
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361 HCT/P regulations will require placentophagy providers to abide
by processing standards that will protect women from the risks
associated with the spread of communicable diseases. 315 The
supplement regulations will ensure that providers are not making
risky and unsubstantiated disease claims that might cause women to
forgo needed treatment. They will also establish a minimum level of
safety.
This scheme would both protect women without
paternalistically deciding what is best for them. Obtaining this
outcome, however, is only possible if FDA uses its discretion to
regulate the product outside of its typical statutory scheme. Without
such enforcement discretion, FDA would be required to follow its own
standards and regulate the product according to Intended Use (as

discussed in Sections II.A and IV.A).
2. FDA Can (and Should) Use Its Enforcement Discretion to Achieve
This Result
FDA occasionally uses its enforcement discretion to regulate
products less stringently than its regulations require. If premarket
review is too harsh for a particular product, it can decline to enforce
those regulations; 316 or if a disease claim has been sufficiently proven
for a particular supplement, it can decline to enforce the supplement
regulations' prohibition of disease claims. 317 In so doing, the agency
will publish on its website a Guidance for Industry, which describes
its enforcement policy for a particular product.3 18 Here, enforcement
discretion would allow the agency to define the product as both a
supplement and a 361 HCT/P. In other words, the agency would be
declining to enforce the full biologic regulations, which are required
for human tissues that do not meet the elements of Section 1271.10.319
Although FDA has never regulated a product under these two

&

315.
See 21 C.F.R. § 1271 (2018).
316.
See e.g., FDA, ENFORCEMENT POLICY, supra note 224, at 2 ("[An IND
sponsor may request a waiver of certain IND regulations applicable to investigators
for those licensed health care providers receiving FMT product to treat patients with
C. difficile infection not responsive to standard therapies.").
317.
See, e.g., Letter from Barbara 0. Schneemann, Dir., Office of Nutrition
Dietary Supplements, to Jonathan W. Emord, (June 19, 2009) (archived at
https://wayback.archive-it.org/7993/20171101205421/https://www.fda.gov/
Food/IngredientsPackagingLabeling/LabelingNutrition/ucml68527.htm).
318.
See, e.g., Summary of Qualified Health Claims Subject to Enforcement
Discretion, supra note 168; FDA, ENFORCEMENT POLICY, supra note 224, at 1.
319.
See 21 C.F.R. § 1271.10 (2018).
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categories before, it does regulate certain products under two different
categories. 320
The Supreme Court has unequivocally upheld FDA's ability to
decline to enforce its provisions, likening it to a prosecutor's discretion
321
One benefit of
to not bring charges against a criminal defendant.
322
its mind if
change
can
FDA
flexibility.
is
its
enforcement discretion
no longer
is
discretion
new facts surface indicating that such
be more
to
warranted, for instance, if the product is revealed
dangerous than expected. This is particularly useful for encapsulated
placenta, where the research on the product is only beginning and our
understanding of the product's safety could change.
FDA has recently exercised enforcement discretion for a product
that threatened similar outcomes if it had been overregulated. As
previewed in Part III, the example is processed, donated stool for fecal
323
Unlike encapsulated
transplants to treat C. difficile infections.
placenta, which might only be providing a placebo benefit, fecal
324
But like encapsulated
transplants have been remarkably effective.
placenta, they suffer from a categorization problem: what exactly is
processed feces? 3 2 5 The agency determined initially that the donated
stool constituted a combination drug-biologic product and would need
326
But after "physicians and scientists
to obtain premarket review.
expressed concern" that the regulations "would make [fecal
transplants] unavailable," FDA decided to not enforce its regulations
so long as certain conditions were met, including the recipient's

320. See, e.g., Is It a Cosmetic, Drug, or Both? (Or Is It Soap?), FOOD & DRUG
https://www.fda.gov/cosmetics/guidanceregulation/
2018),
22,
(Aug.
ADIN.
lawsregulations/ucm074201.htm.
321. Heckler v. Chaney, 470 U.S. 821, 832 (1985).
322. But see, e.g., Lars Noah, Governance by the Backdoor: Administrative
Law(lessness?) at the FDA, 93 NEB. L. REV. 89, 117-18 (2014). In fact, some argue that
enforcement discretion creates lawlessness at an agency because the agency can create
and rescind decisions without any process. Id. ("When the statutory provision sunset
in 2006, the FDA opted to rescind rather than amend the implementing regulation,
which it then replaced with a substantially similar (though, of course, technically
nonbinding) guidance document.").
323. FDA, ENFORCEMENT POLICY, supra note 224, at 2.
See Sachs & Edelstein, supra note 203, at 401 ("[Physicians and scientists]
324.
argued that the available evidence supporting FMT's effectiveness as a therapy for
refractory C. difficile infection was too compelling for regulators to restrict its
availability to the treatment groups of clinical trials.").
Bethany Brookshire, To Regulate Fecal Transplants, FDA Has to First
325.
Answer a Serious Question: What Is Poop?, SCIENCE DAILY (May 18, 2018),
("The first
https://www.sciencenews.org/blog/scicurious/fecal-transplants-regulation
problem is to figure out what an FMT actually is, at least, in terms of how the
government should regulate one.").
FDA, ENFORCEMENT POLICY, supra note 224, at 1 n.1.
326.
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consent and the screening of the donated stool, which cannot come
from a stool bank. 3 2 7 According to FDA, it "developed this
[enforcement discretion] policy to assure that patients with C. difficile
infection not responding to standard therapies may have access to this
treatment, while addressing and controlling the risks that centralized
manufacturing in stool banks presents to subjects." 328 The approach
advocated for in this Article is slightly different in that it would have
FDA regulate a product according to two different categories-one of
which the product does not clearly meet the definition: 361 HCT/P
regulations. Though this is a novel recommendation, if FDA can
regulate a product under harsher regulations (human tissue
biologics), it should be able to exercise its discretion to regulate the
product under a less onerous subset of those regulations (361
HCT/Ps).
There are many commonalities between fecal transplants and
encapsulated placenta that might encourage the agency to similarly
invoke its enforcement discretion. First and foremost, like
encapsulated placenta, the agency was concerned that regulating
donated feces as a drug would obliterate access. Fecal transplants,
like placentophagy, are already widely available, 329 making the
incentives of exclusivity a poor motivator.3 30 Also like encapsulated
placenta, donated stool presents difficulties in scaling up-i.e., even if
exclusivity were granted, it's unclear how a single provider could meet
nationwide demand.3 3 Because both products are made from donated
(or self-donated) human waste, creating a national market is not as
straightforward as products that are made in labs and can be easily
scaled up and mass produced. 332 In fact, FDA decided to exercise its
enforcement discretion after a public outcry that premarket review
would effectively ban the intervention entirely.3 3 3
As previewed in Part III, encapsulated placenta and fecal
transplants share another similarity: the risk that overregulation, by
driving manufacturers from the scene, would create a do-it-yourself
327.
Id. at 2-3.
328.
Id. at 2.
329.
Megan Molteni, Patients Want Poop Transplants. Here's How to Make Them
Safe, WIRED (Dec. 14, 2017, 2:00 PM), https://www.wired.com/story/patients-wantpoop-transplants-heres-how-to-make-them-safe/
("Today, 98 percent of the US
population lives within two hours of a fecal transplant provider.").
330.
See Sachs & Edelstein, supra note 203, at 403-06 (discussing the history of
exclusivity issues as well as those issues as related to FMTs).
331.
Id. at 414.
332.
Id. at 409.
333.
FDA, ENFORCEMENT POLICY, supra note 224, at 2-3; Sachs & Edelstein,
supra note 203, at 400-01.
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industry that is more harmful than the status quo. Fecal transplant
advocates raised this exact concern in arguing for enforcement
discretion from the premarket review regulations: "patients may
resort to essentially free at-home transplantations, using friends or
334
Of
family members, screened at the patient's discretion, as donors."
course, "[u]nsupervised, do-it-yourself treatments carry considerable
risk of the transmission of pathogens from improperly screened and
handled stool." 3 3 5 Any regulatory scheme that would remove
encapsulated placenta from the market would create similar safety
risks for women, as it is one of the few types of products for which a
do-it-yourself industry is easily made. Many women already choose to
336
Placenta
eat the placenta raw, cook it, or encapsulate it themselves.
that is raw or not properly dehydrated contains potentially dangerous
bacteria 337 and is much more likely to cause safety incidents like the
CDC report raised. An industry composed of regulated experts that
must comply with the supplement and 361 HCT/P regulations is
preferable from a safety perspective than unregulated novices. And if
women are no longer allowed to buy encapsulated placenta, they will
very likely produce the product themselves, outside of FDA's control.
Finally, FDA regulation will also encourage more placentophagy
providers to obtain training and certification. Although today there
338
certification's only
are already certification and training programs,
will prefer to
women
benefit is marketing-the possibility that more
buy services from formally trained or certified providers. The
motivation for training and certification will dramatically increase
once the product is regulated and providers realize that FDA can
prosecute them for failing to comply with the 361 HCT/P and
supplement regulations. Individual providers, furthermore, will need
training to understand and comply with the regulatory requirements.
The more that training and certification become integral to
placentophagy production, the safer the product will become for
women.
An FDA enforcement policy regulating encapsulated placenta as
both a supplement and 361 HCT/P is supported by the policy concerns
discussed in Part III. It would neither "leav[e] women alone" nor

334. Sachs & Edelstein, supra note 203, at 406.
Id. at 407.
335.
See, e.g., Hayes, supra note 2, at 79.
336.
Johnson, supra note 69, at 11 ('Potentially pathogenic organisms (E. coli,
337.
Gardnerellavaginalis) were detected in raw placental tissue but were absent after
dehydration.").
See supra text accompanying notes 73-74.
338.
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"undermin[e their] autonomy" by restricting choices. 339 The women
who engage in placentophagy are distrustful of the medical
establishment, which they see as a patriarchal institution that
undervalues women's needs and experiences.3 40 Overregulation of
encapsulated placenta would perpetuate these consumers' feelings
that their preferences are being ignored, especially if the regulations
effectively banned a safe product they relied upon. After all, the
qualitative research suggests that consumers find encapsulated
placenta enormously useful, even if the benefits are largely attributed
to the placebo effect. 34 1 In fact, the tension between access and
protection in encapsulated placenta tracks very closely to the debate
that led to the enactment of the DSHEA. There too, relatively safe
products with unknown benefits were vulnerable to overregulation
that could take them off the market. FDA should resolve the tension
in favor of access, securing a minimum floor by holding encapsulated
placenta to the supplement and 361 HCT/P regulations, which should
adequately protect women. Enforcement discretion allows the agency
to create that perfectly tailored regulatory scheme.
CONCLUSION

Post-partum consumption of encapsulated placenta is no longer a
fringe practice. It comes with significant perceived benefits and also
real risks. FDA has not yet waded into the practice, but it should.
Without any regulation, providers can (and undoubtedly are) making
unsubstantiated promises about the product's ability to prevent or
treat diseases like post-partum depression; some are also undoubtedly
processing the placenta in conditions that could lead to crosscontamination and the spread of bacteria. But the solution should not
be to regulate the product as a drug or biologic, which would remove
from the market a safe product that many women find helpful.
Instead, FDA should tailor regulations narrowly to reduce the harms
the product risks. The 361 HCT/P and supplement regulations
accomplish this goal: they were designed to prevent the spread of
communicable disease, to prohibit manufacturers from making
unsubstantiated disease claims, and to create a safety floor for new
dietary ingredients. Though FDA's regulatory scheme would not yield
this solution on its own, FDA can and should generate this result by
exercising its enforcement discretion, as it has done with similar

339.
340.
341.

Laufer-Ukeles, supra note 232, at 573.
Dickinson et al., supra note 35, at 121-24.
Selander et al., supra note 8, at 105.
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products. This result would balance FDA's competing goals and
ensure that women are neither over- nor under-protected.

